Patent: (prefix with "US" like US6078908)
  1. Patent
    Data
    Compounds
    HGNC
    (for human-derived proteins)
    Patent Title
    Organization
    Deposition
    Downloads
  2. 43
    (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
    Oryzon Genomics, S.A.
    05/11/20
  3. 64
    6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
    Pfizer Inc
    05/11/20
  4. 34
    Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
    Enanta Pharmaceuticals Inc
    05/11/20
  5. 27
    Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
    Dana-Farber Cancer Institute Inc
    05/11/20
  6. 8
    Combination Alzheimer therapy using anti-N3pGlu Abeta antibodies + a BACE inhibitor
    Eli Lilly and Company
    05/11/20
  7. 142
    Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
    Incyte Corporation
    05/11/20
  8. 13
    Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
    eFFECTOR Therapeutics Inc
    05/11/20
  9. 111
    P2X7 Modulators
    Janssen Pharmaceutica NV
    05/11/20
  10. 387
    Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
    Incyte Holdings Corporation
    05/11/20
  11. 24
    Prolyl hydroxylase inhibitors and methods of use
    Akebia Therapeutics, Inc.
    05/11/20
  12. 21
    Pyrazines as modulators of GPR6
    Takeda Pharmaceutical Company Limited
    05/11/20
  13. 143
    Pyrazole compounds and methods of making and using same
    ABIDE THERAPEUTICS, INC.
    05/11/20
  14. 150
    Pyridone derivative, pharmaceutical containing the same and methods of use thereof
    Kaken Pharmaceutical Co., Ltd
    05/11/20
  15. 61
    Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors
    Boehringer Ingelheim International GmbH
    05/11/20
  16. 69
    Substituted pyrrolidines as mGluR5 antagonists
    Hua Medicine (Shanghai) Ltd.
    05/11/20
  17. 135
    Substituted pyrrolizine compounds and uses thereof
    Gilead Sciences Inc
    05/11/20
  18. 217
    TYK2 inhibitors and uses thereof
    Nimbus Lakshmi, Inc.
    05/11/20
  19. 22
    Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors
    Bristol-Myers Squibb Company
    05/11/20
  20. 118
    Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
    Celgene Corporation
    05/11/20
  21. 14
    Triazine carboxamides as sodium channel blockers
    Purdue Pharma LP
    05/11/20
  22. 3
    Urea derivatives and uses thereof
    Kala Pharmaceuticals, Inc.
    05/11/20
  23. 21
    Compounds and methods for inhibiting Cif virulence factor
    Dartmouth College
    05/10/20
  24. 24
    Imidazol- or 1,2,4-triazol-derivatives and their use
    UNIVERSITE DE LILLE 2 DROIT ET SANTE
    05/10/20
  25. 196
    Indole derivatives and their use in neurodegenerative diseases
    Merck Patent GmbH
    05/10/20
  26. 61
    Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure
    UNIVERSITETET I OSLO
    05/10/20
  27. 46
    N-benzoate group substituted benzopyrroline-2-one derivative and use thereof
    Beijing Hanmi Pharmaceutical Co., Ltd.
    05/10/20
  28. 13
    Preparation and use of 7a-heterocycle substituted-6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
    TBA
    05/10/20
  29. 6
    Pyrazolylaminobenzimidazole derivatives as JAK inhibitors
    Eli Lilly and Company
    05/10/20
  30. 638
    Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors
    Array BioPharma Inc
    05/10/20
  31. 227
    Quinazoline and quinoline compounds and uses thereof
    Millennium Pharmaceuticals Inc
    05/10/20
  32. 19
    Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
    Beijing Tide Pharmaceutical Co., Ltd
    05/10/20
  33. 365
    Sphinogosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders
    The Scripps Research Institute
    05/10/20
  34. 13
    Substituted piperidinyl tetrahydroquinolines
    Bayer Pharma Aktiengesellschaft
    05/10/20
  35. 114
    Triazoles as NR2B receptor inhibitors
    JANSSEN PHARMACEUTICALS, INC.
    05/10/20
  36. 11
    10-substituted morphinan hydantoins
    Purdue Pharma LP
    05/07/20
  37. 32
    1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
    Respivert Ltd
    05/05/20
  38. 10
    2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof
    Georgetown University
    05/05/20
  39. 138
    Compositions useful for treating disorders related to kit
    BLUEPRINT MEDICINES CORPORATION
    05/05/20
  40. 129
    Cyclopropylamines as LSD1 inhibitors
    Incyte Corporation
    05/05/20
  41. 16
    H3 antagonists containing phenoxypiperidine core structure
    Richter Gedeon Nyrt.
    05/05/20
  42. 149
    Heteroarylamide inhibitors of TBK1
    Takeda Pharmaceutical Company Limited
    05/05/20
  43. 8
    Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
    3-V Biosciences, Inc.
    05/05/20
  44. 54
    Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors
    Sunovion Pharmaceuticals Inc
    05/05/20
  45. 33
    Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
    Principia Biopharma Inc
    05/05/20
  46. 43
    Trk-inhibiting compound
    Ono Pharmaceutical Co., Ltd
    05/05/20
  47. 13
    7-beta-alkyl analogs of orvinols
    Purdue Pharma LP
    04/30/20
  48. 47
    N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
    Ogeda SA
    04/30/20
  49. 24
    5,5-bicyclic oxazole orexin receptor antagonists
    Merck Sharp & Dohme Corp
    04/25/20
  50. 8
    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Jenrin Discovery Inc
    04/25/20
  51. 33
    Inhibitors of lysine gingipain
    CORTEXYME, INC.
    04/25/20
  52. 31
    Pharmaceutical composition comprising pyridone derivatives
    SK Biopharmaceuticals Co. Ltd
    04/25/20
  53. 41
    Pharmaceutical composition for treating FLT3 mutation-positive cancer, mutant FLT3 inhibitor and uses thereof
    FUJIFILM Corporation
    04/25/20
  54. 5
    Primary amines and derivitves thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
    Arena Pharmaceuticals Inc
    04/25/20
  55. 239
    Substituted 2,4-diaminopyrimidines as kinase inhibitors
    Celgene CAR LLC
    04/25/20
  56. 29
    3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors
    Janssen Pharmaceutica NV
    04/18/20
  57. 124
    GDF-8 inhibitors
    Rigel Pharmaceuticals, Inc
    04/18/20
  58. 73
    IRE-1α inhibitors
    FOSUN ORINOVE PHARMATECH, INC.
    04/18/20
  59. 146
    Pyrrolotriazine compounds as tam inhibitors
    Incyte Corporation
    04/18/20
  60. 296
    Serotonin receptor modulators
    Janssen Pharmaceutica NV
    04/18/20
  61. 74
    Substituted benzo[d][1,2,3]triazines as p70S6K inhibitors
    Merck Patent GmbH
    04/18/20
  62. 116
    Triazoles as NR2B receptor inhibitors
    JANSSEN PHARMACEUTICALS, INC.
    04/18/20
  63. 10
    Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
    NewLink Genetics Corporation
    04/18/20
  64. 73
    Trifluoromethylpropanamide derivatives
    Hoffman-La Roche Inc
    04/18/20
  65. 17
    β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators
    Samumed, LLC
    04/15/20
  66. 23
    1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
    Takeda Pharmaceutical Company Limited
    04/15/20
  67. 40
    1H-pyrrol-3-amines
    Bayer Pharma Aktiengesellschaft
    04/15/20
  68. 18
    Apoptosis signal-regulating kinase inhibitors
    Gilead Sciences Inc
    04/15/20
  69. 80
    Aromatic heterocyclic compound
    Mitsubishi Tanabe Pharma Corporation
    04/15/20
  70. 170
    Compounds and compositions for inhibiting the activity of SHP2
    Novartis AG
    04/15/20
  71. 3
    Fucosidase inhibitors
    HORIZON ORPHAN LLC
    04/15/20
  72. 10
    Heterocyclic compounds and methods for their use
    Novartis AG
    04/15/20
  73. 267
    Heterocyclic compounds as immunomodulators
    Incyte Corporation
    04/15/20
  74. 163
    Heterocyclic compounds as inhibitors of Vanin-1 enzyme
    Pfizer Inc
    04/15/20
  75. 3
    Inhibitors of PTP4A3 for the treatment of cancer
    University of Virginia Patent Foundation
    04/15/20
  76. 15
    Inhibitors of cyclin-dependent kinase 7 (CDK7)
    Syros Pharmaceuticals, Inc.
    04/15/20
  77. 18
    Methods of use of cyclopamine analogs
    Infinity Pharmaceuticals Inc
    04/15/20
  78. 74
    Muscarinic M1 receptor positive allosteric modulators
    Suven Life Sciences Limited
    04/15/20
  79. 167
    Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
    Boehringer Ingelheim International GmbH
    04/15/20
  80. 43
    Piperidine oxadiazole and thiadiazole orexin receptor antagonists
    Merck Sharp & Dohme Corp
    04/15/20
  81. 18
    Preparation and use of kinase inhibitor
    CHANGZHOU LONGTHERA PHARMACEUTICALS INC.
    04/15/20
  82. 14
    Proton pump inhibitors
    Takeda Pharmaceutical Company Limited
    04/15/20
  83. 121
    Pyridine derivatives
    Hoffmann-La Roche Inc
    04/15/20
  84. 34
    Pyridinyl and fused pyridinyl triazolone derivatives
    Takeda Pharmaceutical Company Limited
    04/15/20
  85. 22
    Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
    Bayer Pharma Aktiengesellschaft
    04/15/20
  86. 673
    Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
    Epizyme Inc
    04/15/20
  87. 16
    Therapeutic compounds and compositions, and methods of use thereof
    Genentech Inc
    04/15/20
  88. 238
    Therapeutic compounds and uses thereof
    Genentech Inc
    04/15/20
  89. 310
    Therapeutic inhibitory compounds
    LIFESCI PHARMACEUTICALS, INC.
    04/15/20
  90. 28
    Thienopyranones as kinase and epigenetic inhibitors
    Signal Rx Pharmaceuticals Inc
    04/15/20
  91. 60
    Tricyclic heterocyclic compounds useful as inhibitors of TNF
    Bristol-Myers Squibb Company
    04/15/20
  92. 31
    2-pyridyloxy-3-ester-4-ether orexin receptor antagonists
    Merck Sharp & Dohme Corp
    04/10/20
  93. 36
    Aromatic heterocyclic derivatives and pharmaceutical applications thereof
    Sunshine Lake Pharma Co., Ltd
    04/10/20
  94. 2
    Arylpiperazine derivatives and methods of utilizing same
    Reviva Pharmaceuticals Inc
    04/10/20
  95. 10
    Benzimidazole derivatives and use thereof
    Purdue Pharma LP
    04/10/20
  96. 3
    Benzomorphan analogs and use thereof
    Purdue Pharma LP
    04/10/20
  97. 11
    Compounds for the inhibition of cyclophilins and uses thereof
    Merck Patent GmbH
    04/10/20
  98. 4
    Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer''s disease
    FONDAZIONE ISTITUTO ITAIANO DI TECNOLOGIA
    04/10/20
  99. 44
    Factor XIa inhibitors
    Merck Sharp & Dohme Corp
    04/10/20
  100. 63
    Heteroaromatic compounds as BTK inhibitors
    Boehringer Ingelheim International GmbH
    04/10/20
  101. 80
    Pyrimidinones as PI3K inhibitors
    Incyte Holdings Corporation
    04/10/20
  102. 50
    3-(4-(benzyloxy)phenyl)hex-4-ynoic acid derivative, method of preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient
    HYUNDAI PHARM CO., LTD
    04/06/20
  103. 122
    Compounds useful as CCR9 modulators
    Norgine B.V.
    04/06/20
  104. 53
    Factor IXa inhibitors
    Merck Sharp & Dohme Corp
    04/06/20
  105. 166
    Inhibitors of IRAK4 activity
    Merck Sharp & Dohme Corp
    04/06/20
  106. 190
    Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof
    Sanford-Burnham Medical Research Institute
    04/06/20
  107. 6
    N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
    Ogeda SA
    04/06/20
  108. 8
    P2X4 receptor antagonist
    Nippon Chemiphar Co., Ltd
    04/06/20
  109. 10
    Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
    Rugen Holdings (Cayman) Limited
    04/06/20
  110. 9
    Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them
    Wisconsin Alumni Research Foundation
    04/06/20
  111. 130
    Urea and amide derivatives of aminoalkylpiperazines and use thereof
    Southern Research Institute
    04/06/20
  112. 1
    Morphinan derivative
    University of Tsukuba
    03/30/20
  113. 117
    N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof
    Northeastern University
    03/30/20
  114. 220
    N-arylmethyl sulfonamide negative modulators of NR2A
    Luc Therapeutics, Inc.
    03/30/20
  115. 26
    Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
    Genentech Inc
    03/30/20
  116. 40
    Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof
    Taiho Pharmaceutical Co., Ltd
    03/30/20
  117. 45
    Pyrrolopyrimidine compounds used as TLR7 agonist
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd
    03/30/20
  118. 13
    Radiolabeled compounds
    Takeda Pharmaceutical Company Limited
    03/30/20
  119. 18
    Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase
    University of Washington Through its Center for Commercialization
    03/30/20
  120. 43
    Substituted pyrazino[1,2-a]indoles as sigma receptor activity modulators
    LABORATORIOS DEL DR. ESTEVE S.A.
    03/30/20
  121. 15
    Sulfonamide compounds for inhibition of metastatic tumor growth
    Welichem Biotech Inc.
    03/30/20
  122. 12
    Use of small molecule inhibitors targeting EYA tyrosine phosphatase
    Children''s Hospital Medical Center
    03/30/20
  123. 25
    Compositions and methods of modulating 15-PGDH activity
    University of Kentucky Research Foundation
    03/26/20
  124. 63
    Heteroaromatic derivatives and their use as pharmaceuticals
    Mutabilis
    03/26/20
  125. 61
    Histone deacetylase inhibitors
    BioMarin Pharmaceutical Inc
    03/26/20
  126. 31
    Imidazole derivative having JNK inhibitory activity and use thereof
    SAMJIN PHARMACEUTICAL CO., LTD.
    03/26/20
  127. 365
    Inhibitors of ERK and methods of use
    Kura Oncology Inc
    03/26/20
  128. 15
    Kinase inhibitors
    Topivert Pharma Limited
    03/26/20
  129. 33
    Phosphonate compounds for treatment of complement mediated disorders
    Achillion Pharmaceuticals Inc
    03/26/20
  130. 33
    Piperazine derivative
    Astellas Pharma Inc
    03/26/20
  131. 180
    Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors
    Bristol-Myers Squibb Company
    03/26/20
  132. 62
    Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
    Guangzhou Innocare Pharma Tech Co., Ltd.
    03/26/20
  133. 139
    Therapeutic inhibitory compounds
    LIFESCI PHARMACEUTICALS, INC.
    03/26/20
  134. 54
    1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
    Novartis AG
    03/25/20
  135. 14
    CGRP receptor antagonists
    Heptares Therapeutics Limited
    03/25/20
  136. 306
    Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ]
    Phenex Pharmaceuticals AG
    03/25/20
  137. 153
    Compounds and methods for kinase modulation, and indications therefor
    Plexxikon Inc.
    03/25/20
  138. 61
    Cyclopropylamines as LSD1 inhibitors
    Incyte Corporation
    03/25/20
  139. 41
    Imidazole derivatives as formyl peptide receptor modulators
    Allergan Inc
    03/25/20
  140. 118
    Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
    Zhejiang DTRM Biopharma Co. Ltd
    03/25/20
  141. 53
    Tetrahydropyridopyrimidine compound or salt thereof
    Taiho Pharmaceutical Co., Ltd
    03/25/20
  142. 87
    Therapeutic compounds and uses thereof
    Genentech Inc
    03/25/20
  143. 53
    Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
    UNIVERSITAT BERN
    03/25/20
  144. 43
    Trk-inhibiting compound
    Ono Pharmaceutical Co., Ltd
    03/25/20
  145. 18
    Tyrosine kinase inhibitor and uses thereof
    Xuanzhu Pharma Co., Ltd
    03/25/20
  146. 40
    Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
    Sanford Burnham Prebys Medical Discovery Institute
    03/25/20
  147. 88
    1H-pyrrolo[2,3,c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
    Incyte Corporation
    03/23/20
  148. 103
    5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum
    University of Washington Through its Center for Commercialization
    03/23/20
  149. 59
    6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives
    Hoffman-La Roche Inc
    03/23/20
  150. 139
    Benzimidazol-2-amines as mIDH1 inhibitors
    Bayer Pharma Aktiengesellschaft
    03/23/20
  151. 184
    Bromodomain inhibitors
    AbbVie Inc
    03/23/20
  152. 44
    CDK inhibitors
    GI Therapeutics, Inc.
    03/23/20
  153. 4
    Compounds for the treatment of cancer and inflammatory diseases
    TBA
    03/23/20
  154. 423
    Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors
    Merck Sharp & Dohme Corp
    03/23/20
  155. 75
    N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors
    Merck Sharp & Dohme Corp
    03/23/20
  156. 21
    Selective histone deactylase 6 inhibitors
    H. Lee Moffitt Cancer Center and Research Institute Inc
    03/23/20
  157. 61
    Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
    BEIJING INNOCARE PHARMA TECH CO., LTD.
    03/18/20
  158. 147
    8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives
    IDORSIA PHARMACEUTICALS Ltd
    03/16/20
  159. 116
    Aminopyridazinone compounds as protein kinase inhibitors
    Jiangsu Hengrui Medicine Co., Ltd.
    03/16/20
  160. 346
    Benzimidazol-2-amines as MIDH1 inhibitors
    Bayer Pharma Aktiengesellschaft
    03/16/20
  161. 219
    Dihydropyridone P1 as factor XIa inhibitors
    Bristol-Myers Squibb Company
    03/16/20
  162. 13
    Heterocyclic vinyl autotaxin inhibitor compounds
    PharmAkea Inc
    03/16/20
  163. 154
    Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors
    Proximagen Limited
    03/16/20
  164. 305
    Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments
    Bayer Pharma Aktiengesellschaft
    03/16/20
  165. 25
    Inhibitors of beta-secretase
    Vitae Pharmaceuticals Inc
    03/16/20
  166. 236
    Isoquinolin-3-yl carboxamides and preparation and use thereof
    Samumed, LLC
    03/16/20
  167. 35
    Mammalian and bacterial nitric oxide synthase inhibitors
    Northwestern University
    03/16/20
  168. 28
    Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
    iTeos Therapeutics
    03/16/20
  169. 3
    Selective matrix metalloproteinase inhibitors
    University of Notre Dame du Lac
    03/16/20
  170. 63
    Styryl quinazoline derivatives as pharmaceutically active agents
    Vichem Chemie Kutató
    03/16/20
  171. 23
    Tertiary amines for use in the treatment of cardiac disorders
    UNIVERSITETET I OSLO
    03/16/20
  172. 43
    (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
    Oryzon Genomics, S.A.
    03/12/20
  173. 109
    Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
    Incyte Holdings Corporation
    03/12/20
  174. 5
    Cannabinoid receptor modulators
    Arena Pharmaceuticals Inc
    03/12/20
  175. 8
    Factor XIa inhibitors
    Merck Sharp & Dohme Corp
    03/12/20
  176. 138
    Heterocyclic compounds as LSD1 inhibitors
    Incyte Corporation
    03/12/20
  177. 205
    Imidazotriazines and imidazopyrimidines as kinase inhibitors
    Incyte Corporation
    03/12/20
  178. 167
    Inhibiting neurotransmitter reuptake
    Mayo Foundation for Medical Education and Research
    03/12/20
  179. 17
    Inhibitors of IRAK4 activity
    Merck Sharp & Dohme Corp
    03/12/20
  180. 103
    Oxazole compound and pharmaceutical composition
    Otsuka Pharmaceutical Co., Ltd
    03/12/20
  181. 61
    Substituted amino triazoles useful as human chitinase inhibitors
    OncoArendi Therapeutics SA
    03/12/20
  182. 57
    1, 3, 4-thiadiazole compounds and their use in treating cancer
    AstraZeneca AB
    03/10/20
  183. 11
    3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
    Rugen Holdings (Cayman) Limited
    03/10/20
  184. 150
    4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity
    VIROSTATICS SRL
    03/10/20
  185. 21
    Compounds
    UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
    03/10/20
  186. 2
    Compounds as rearranged during transfection (RET) inhibitors
    GlaxoSmithKline Intellectual Property Development Limited
    03/10/20
  187. 27
    Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators
    Suven Life Sciences Limited
    03/10/20
  188. 398
    Heteroaryl substituted aminopyridine compounds
    Bristol-Myers Squibb Company
    03/10/20
  189. 273
    Inhibitors of the kynurenine pathway
    CURADEV PHARMA, PVT. LTD.
    03/10/20
  190. 47
    Oxazoline and isoxazoline derivatives as CRAC modulators
    LUPIN LIMITED
    03/10/20
  191. 3
    Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof
    Tianjin Institute of Pharmaceutical Research
    03/10/20
  192. 80
    Positive allosteric modulators of human melanocortin-4 receptor
    Vanderbilt University
    03/10/20
  193. 129
    Quinolone derivatives as fibroblast growth factor receptor inhibitors
    Principia Biopharma Inc
    03/10/20
  194. 15
    Small molecule inhibitors of the JAK family of kinases
    Janssen Pharmaceutica NV
    03/10/20
  195. 135
    Substituted boronic acids and boronate esters as immunoproteasome inhibitors
    Merck Patent GmbH
    03/10/20
  196. 36
    TGF beta receptor antagonists
    Bristol-Myers Squibb Company
    03/10/20
  197. 33
    1,3,4-thiadiazole compounds and their use in treating cancer
    AstraZeneca AB
    03/02/20
  198. 81
    6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
    Merck Sharp & Dohme Corp
    03/02/20
  199. 34
    C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
    Merck Patent GmbH
    03/02/20
  200. 116
    Cyclopropanecarboxylic acid GPR120 modulators
    Bristol-Myers Squibb Company
    03/02/20
  201. 668
    Heterocyclic inhibitors of glutaminase
    Calithera Biosciences Inc
    03/02/20
  202. 34
    Hydrazine compound as blood coagulation factor Xa inhibitor
    North China Pharmaceutical Company., Ltd.
    03/02/20
  203. 22
    Naphthyridine compounds, medical combinations and use thereof
    NANJING NATINEFY PHARMATECH CO., LTD.
    03/02/20
  204. 25
    Substituted heteroaryl compounds and methods of use
    CALITOR SCIENCES, LLC
    03/02/20
  205. 9
    Therapeutic pyrazolyl thienopyridines
    FBM THERAPEUTICS, LLC
    03/02/20
  206. 13
    Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
    Karus Therapeutics Limited
    03/02/20
  207. 260
    Compounds
    Takeda Pharmaceutical Company Limited
    02/29/20
  208. 66
    Pyridazinone compounds and their use as DAAO inhibitors
    Takeda Pharmaceutical Company Limited
    02/29/20
  209. 70
    3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
    Samumed, LLC
    02/27/20
  210. 66
    3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
    Samumed, LLC
    02/27/20
  211. 43
    5-hydroxytryptamine receptor 7 activity modulators and their method of use
    TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    02/27/20
  212. 3
    Amino pyrimidine SSAO inhibitors
    Eli Lilly and Company
    02/27/20
  213. 698
    Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
    Achillion Pharmaceuticals Inc
    02/27/20
  214. 22
    Bicyclic heterocyclic compounds as PDE2 inhibitors
    Merck Sharp & Dohme Corp
    02/27/20
  215. 129
    CXCR7 antagonists
    ChemoCentryx, Inc.
    02/27/20
  216. 37
    Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
    AstraZeneca AB
    02/27/20
  217. 14
    Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies
    Galderma Research & Development
    02/27/20
  218. 30
    Compounds for treatment of fibrosis diseases
    CUREGENIX, INC.
    02/27/20
  219. 64
    Heterocyclic derivatives as modulators of kinase activity
    Merck Patent GmbH
    02/27/20
  220. 4
    Imidazolyl kinase inhibitors and uses thereof
    Dana-Farber Cancer Institute Inc
    02/27/20
  221. 39
    Inhibitors of human 12/15-lipoxygenase
    THE CHILDREN'S HOSPITAL CORPORATION
    02/27/20
  222. 304
    Isoquinolin-3-yl carboxamides and preparation and use thereof
    Samumed, LLC
    02/27/20
  223. 35
    Morphan and morphinan analogues, and methods of use
    ALKERMES PHARMA IRELAND LIMITED
    02/27/20
  224. 197
    Pyrimidinone amide compounds as PDE2 inhibitors
    Merck Sharp & Dohme Corp
    02/27/20
  225. 126
    Substituted indazole compounds as RORgammaT inhibitors and uses thereof
    Merck Sharp & Dohme Corp
    02/27/20
  226. 261
    Substituted piperidine compound and use thereof
    Takeda Pharmaceutical Company Limited
    02/27/20
  227. 51
    Substituted pyrimidines containing acidic groups as TLR7 modulators
    APROS THERAPEUTICS, INC.
    02/27/20
  228. 303
    TGF-β inhibitors
    Rigel Pharmaceuticals, Inc
    02/27/20
  229. 125
    2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof
    Samumed, LLC
    02/24/20
  230. 14
    Benzimidazole derivatives as RLK and ITK inhibitors
    Principia Biopharma Inc
    02/24/20
  231. 166
    Compounds, compositions, and methods
    Denali Therapeutics Inc.
    02/24/20
  232. 2
    FXR (NR1H4) modulating compounds
    Gilead Sciences Inc
    02/24/20
  233. 98
    Heterocyclic inhibitors of PTPN11
    The University of Texas System
    02/24/20
  234. 69
    Heterocyclic kinase inhibitors
    AbbVie Inc
    02/24/20
  235. 101
    Inhibitors of IRAK4 activity
    Merck Sharp & Dohme Corp
    02/24/20
  236. 39
    Purine derivatives for the treatment of viral infections
    Janssen Sciences Ireland UC
    02/24/20
  237. 5
    Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof
    The Council of Scientific & Industrial Research
    02/24/20
  238. 7
    Syk inhibitors
    Gilead Sciences Inc
    02/24/20
  239. 112
    Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders
    Incyte Corporation
    02/24/20
  240. 15
    Combination therapy with glutaminase inhibitors
    Calithera Biosciences Inc
    02/21/20
  241. 36
    Identification of stabilizers of multimeric proteins
    The Board of Trustees of the Leland Stanford Junior University
    02/21/20
  242. 26
    Phthalazinone compounds and methods for the treatment of cystic fibrosis
    Flatley Discovery Lab LLC
    02/21/20
  243. 16
    Pyrazolopyridone compounds and uses thereof
    Incyte Corporation
    02/21/20
  244. 213
    Pyridazine derivatives as RORc modulators
    Genentech Inc
    02/21/20
  245. 40
    Pyridopyrimidinones and methods of use thereof
    Genentech Inc
    02/21/20
  246. 183
    Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
    FORMA TM2, INC.
    02/21/20
  247. 2
    Salt of fused pyrimidine compound and crystal thereof
    Taiho Pharmaceutical Co., Ltd
    02/21/20
  248. 172
    Serine/threonine kinase inhibitors
    Genentech Inc
    02/21/20
  249. 219
    Therapeutic compounds and uses thereof
    Genentech Inc
    02/21/20
  250. 11
    Tricyclic analogues, preparation method and uses thereof
    Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    02/21/20
  251. 26
    Compounds that are S1P modulating agents and/or ATX modulating agents
    BIOGEN MA INC.
    02/20/20
  252. 163
    Histone demethylase inhibitors
    CELGENE QUANTSCEL RESEARCH, INC.
    02/20/20
  253. 475
    Inhibitors of glucocorticoid receptor translocation
    Sanford Burnham Prebys Medical Discovery Institute
    02/20/20
  254. 5
    Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
    Exelixis Inc
    02/20/20
  255. 180
    NHE3-binding compounds and methods for inhibiting phosphate transport
    ARDELYX, INC.
    02/20/20
  256. 83
    NRF2 regulators
    GlaxoSmithKline Intellectual Propert Development Limited
    02/20/20
  257. 14
    Piperidinone carboxamide azaindane CGRP receptor antagonists
    Merck Sharp & Dohme Corp
    02/20/20
  258. 8
    Pteridines as FGFR inhibitors
    Astex Therapeutics Ltd
    02/20/20
  259. 21
    Pyrazines as modulators of GPR6
    Takeda Pharmaceutical Company Limited
    02/20/20
  260. 389
    Substituted 6,5-fused bicyclic heteroaryl compounds
    Epizyme Inc
    02/20/20
  261. 173
    Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators
    Indivior UK Limited
    02/20/20
  262. 15
    Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
    Piramal Enterprises Limited
    02/20/20
  263. 39
    Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
    Emory University
    02/20/20
  264. 804
    Tricyclic sulfones as RORγ modulators
    Bristol-Myers Squibb Company
    02/20/20
  265. 15
    2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
    Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
    02/16/20
  266. 130
    Aldosterone synthase inhibitors
    Boehringer Ingelheim International GmbH
    02/16/20
  267. 23
    Benzazepine sulfonamide compounds
    Hoffmann-La Roche Inc
    02/16/20
  268. 52
    Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
    Incyte Corporation
    02/16/20
  269. 37
    Bicyclic heterocycles as FGFR4 inhibitors
    Incyte Corporation
    02/16/20
  270. 3
    Compounds I
    Proximagen Limited
    02/16/20
  271. 168
    Imidazopyrrolidine derivatives and their use in the treatment of disease
    Novartis AG
    02/16/20
  272. 169
    Urea derivatives useful as kinase inhibitors
    Respivert Limited
    02/16/20
  273. 451
    5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis
    Galapagos NV
    02/10/20
  274. 13
    Bipyrazole derivatives as JAK inhibitors
    Incyte Corporation
    02/10/20
  275. 33
    Inhibition of MCL-1 and/or BFL-1/A1
    Dana-Farber Cancer Institute Inc
    02/10/20
  276. 53
    Inhibitors of IRAK4 activity
    Merck Sharp & Dohme Corp
    02/10/20
  277. 34
    Inhibitors of bruton's tyrosine kinase
    Centaurus BioPharma Co., Ltd
    02/10/20
  278. 401
    Phthalazinones and isoquinolinones as rock inhibitors
    Bristol-Myers Squibb Company
    02/10/20
  279. 53
    Tetracyclic autotaxin inhibitors
    PharmAkea Inc
    02/10/20
  280. 11
    2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
    Gilead Sciences Inc
    02/07/20
  281. 22
    2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof
    Merck Patent GmbH
    02/07/20
  282. 27
    3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof
    St. Chuan University
    02/07/20
  283. 71
    6-membered cyclic amines or lactames substituted with urea and phenyl
    GRÜNENTHAL GMBH
    02/07/20
  284. 26
    Bacterial topoisomerase I inhibitors with antibacterial activity
    THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    02/07/20
  285. 109
    Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
    Incyte Corporation; Incyte Holdings Corporation
    02/07/20
  286. 64
    Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
    Enanta Pharmaceuticals Inc
    02/07/20
  287. 13
    Branched 3-phenylpropionic acid derivatives and their use
    Bayer Intellectual Property GmbH
    02/07/20
  288. 134
    Bruton's tyrosine kinase inhibitors
    Pfizer Inc
    02/07/20
  289. 168
    Carbazole derivatives
    Bristol-Myers Squibb Company
    02/07/20
  290. 118
    Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof
    Sunshine Lake Pharma Co., Ltd
    02/07/20
  291. 26
    Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
    GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.
    02/07/20
  292. 18
    EZH2 inhibitors
    Mirati Therapeutics Inc
    02/07/20
  293. 29
    Inhibitor of FLT3 kinase and use thereof
    HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    02/07/20
  294. 4
    Psychotropic agents and uses thereof
    LB PHARMACEUTICALS INC.
    02/07/20
  295. 932
    Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
    Epizyme Inc
    02/07/20
  296. 187
    Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases
    Bayer Intellectual Property GmbH
    02/07/20
  297. 258
    Tank-binding kinase inhibitor compounds
    Gilead Sciences Inc
    02/07/20
  298. 144
    Therapeutic inhibitory compounds
    LIFESCI PHARMACEUTICALS, INC.
    02/07/20
  299. 106
    Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
    Incyte Corporation
    02/07/20
  300. 70
    Thioacetate compounds, compositions and methods of use
    Ardea Biosciences, Inc.
    02/07/20
  301. 343
    ULK1 inhibitors and methods using same
    SALK INSTITUTE FOR BIOLOGICAL STUDIES
    02/07/20
  302. 155
    Compounds and their use as BACE inhibitors
    AstraZeneca AB
    02/04/20
  303. 109
    Cyclopropanamine compound and use thereof
    Takeda Pharmaceutical Company Limited
    02/04/20
  304. 168
    Heterocyclic compounds useful as pim kinase inhibitors
    Incyte Corporation
    02/04/20
  305. 218
    Indole carboxamide compounds
    Bristol-Myers Squibb Company
    02/04/20
  306. 30
    Methyl oxazole orexin receptor antagonists
    Merck Sharp & Dohme Corp
    02/04/20
  307. 104
    Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
    Pfizer Inc
    02/04/20
  308. 35
    N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system
    CHRONOS THERAPEUTICS LIMITED
    02/04/20
  309. 79
    Pyrazolo[3,4-d]pyrimidine compound or salt thereof
    Taiho Pharmaceutical Co., Ltd
    02/04/20
  310. 2
    Pyridone derivatives as rearranged during transfection (RET) kinase inhibitors
    GlaxoSmithKline Intellectual Property Development Limited
    02/04/20
  311. 14
    Substituted oxopyridine derivatives and use thereof as factor XIa/plasma
    Bayer Pharma Aktiengesellschaft
    02/04/20
  312. 111
    Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
    Incyte Corporation
    02/04/20
  313. 78
    Heteroaryl Syk inhibitors
    Boehringer Ingelheim International GmbH
    01/30/20
  314. 30
    Naphthylamide compound, preparation method and use thereof
    Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    01/30/20
  315. 156
    Pyrazolo[1,5-a]pyridine derivatives and methods of their use
    IGNYTA, INC.
    01/30/20
  316. 113
    TrKA kinase inhibitors, compositions and methods thereof
    Merck Sharp & Dohme Corp
    01/30/20
  317. 404
    Tricyclic pyrido-carboxamide derivatives as rock inhibitors
    Bristol-Myers Squibb Company
    01/30/20
  318. 11
    Use of benzimidazole-proline derivatives
    IDORSIA PHARMACEUTICALS Ltd
    01/30/20
  319. 45
    Apoptosis signal-regulating kinase inhibitors
    Gilead Sciences Inc
    01/27/20
  320. 65
    Aryl ethers and uses thereof
    PELOTON THERAPEUTICS, INC.
    01/27/20
  321. 132
    Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof
    Agency for Science, Technology and Research
    01/27/20
  322. 48
    Histone deacetylase inhibitors
    BioMarin Pharmaceutical Inc
    01/27/20
  323. 154
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    01/27/20
  324. 198
    Kinase inhibitors and method of treating cancer
    University Health Network
    01/27/20
  325. 8
    Methods to treat lymphoplasmacytic lymphoma
    Dana-Farber Cancer Institute Inc
    01/27/20
  326. 84
    Spirocyclic derivatives
    CHRONOS THERAPEUTICS LIMITED
    01/27/20
  327. 88
    Tricyclic fused thiophene derivatives as JAK inhibitors
    Incyte Corporation
    01/27/20
  328. 32
    1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions
    SABILA BIOSCIENCES LLC
    01/21/20
  329. 135
    4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors
    Janssen Pharmaceutica NV
    01/21/20
  330. 41
    Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Enanta Pharmaceuticals Inc
    01/21/20
  331. 65
    Aryl ethers and uses thereof
    PELOTON THERAPEUTICS, INC.
    01/21/20
  332. 5
    Assays for screening for or identifying an agent or molecule that can block or inhibit AVB3 integrin from forming a complex with KRAS
    The Regents of the University of California
    01/21/20
  333. 101
    Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
    Novartis AG
    01/21/20
  334. 330
    Benzenesulfonamide compounds and their use as therapeutic agents
    Xenon Pharmaceuticals Inc
    01/21/20
  335. 235
    Biaryl kinase inhibitors
    Bristol-Myers Squibb Company
    01/21/20
  336. 186
    Bicyclic heterocycles as FGFR4 inhibitors
    Incyte Corporation
    01/21/20
  337. 88
    Chemokine receptor modulators and uses thereof
    FLX BIO, INC.
    01/21/20
  338. 243
    Compounds, compositions and methods
    Denali Therapeutics Inc.
    01/21/20
  339. 9
    Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors
    Palobiofarma, S.L.
    01/21/20
  340. 18
    Diaryl macrocycles as modulators of protein kinases
    TP Therapeutics, Inc.
    01/21/20
  341. 57
    Fused tricyclic compounds as Raf kinase inhibitors
    BeiGene, Ltd
    01/21/20
  342. 106
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    01/21/20
  343. 509
    IRAK4 inhibiting agents
    BIOGEN MA INC.
    01/21/20
  344. 53
    Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Boehringer Ingelheim International GmbH
    01/21/20
  345. 28
    Indazole and azaindazole Btk inhibitors
    Merck Sharp & Dohme Corp
    01/21/20
  346. 51
    Inhibiting G protein coupled receptor 6 kinase polypeptides
    Mayo Foundation for Medical Education and Research
    01/21/20
  347. 31
    Inhibitors of lysine specific demethylase-1
    Celgene Quanticel Research Inc
    01/21/20
  348. 46
    Macrocyclic compounds as TRK kinase inhibitors
    Array BioPharma Inc
    01/21/20
  349. 227
    N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
    Novartis AG
    01/21/20
  350. 31
    N-pyrrolidinyl,N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
    Array BioPharma Inc
    01/21/20
  351. 13
    Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition
    PEKING UNIVERSITY FOUNDER GROUP CO., LTD.
    01/21/20
  352. 85
    Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
    FORMA TM2, INC.
    01/21/20
  353. 4
    Pyridone-sulfone morphinan analogs as opioid receptor ligands
    Purdue Pharma LP
    01/21/20
  354. 7
    Quinoxaline derivatives useful as FGFR kinase modulators
    Astex Therapeutics Ltd
    01/21/20
  355. 57
    Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors
    Boehringer Ingelheim International GmbH
    01/21/20
  356. 168
    Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
    EXONHIT THERAPEUTICS, SA
    01/21/20
  357. 365
    Substituted prolines/piperidines as orexin receptor antagonists
    EOLAS THERAPEUTICS, INC.
    01/21/20
  358. 232
    Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
    Array BioPharm Inc.
    01/21/20
  359. 609
    Tank-binding kinase inhibitor compounds
    Gilead Sciences Inc
    01/21/20
  360. 46
    TrkA kinase inhibitors, compositions and methods thereof
    Merck Sharp & Dohme Corp
    01/21/20
  361. 32
    1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors
    Respivert Limited
    12/30/19
  362. 620
    2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG
    Cancer Research Technology Limited
    12/30/19
  363. 16
    3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
    Parion Sciences Inc
    12/30/19
  364. 22
    4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators
    Heptares Therapeutics Limited
    12/30/19
  365. 132
    4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
    Merck Sharp & Dohme B.V.
    12/30/19
  366. 43
    5-hydroxytryptamine receptor 7 activity modulators and their method of use
    TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    12/30/19
  367. 22
    Benzoazepine derivatives
    ViiV HEALTHCARE UK LIMITED
    12/30/19
  368. 48
    Benzothiazole and benzothiophene compounds
    Universite de Montreal
    12/30/19
  369. 1057
    Biaryl amide compounds as kinase inhibitors
    Novartis AG
    12/30/19
  370. 49
    C5-C6-fused tricyclic iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
    TBA
    12/30/19
  371. 190
    Dopamine D3 receptor antagonists
    Indivior UK Limited
    12/30/19
  372. 53
    Heteroaryl orexin receptor antagonists
    Merck Sharp & Dohme Corp
    12/30/19
  373. 12
    Liver X receptor (LXR) modulators
    RALEXAR THERAPEUTICS, INC.
    12/30/19
  374. 357
    Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
    Boehringer Ingelheim International GmbH
    12/30/19
  375. 141
    N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B
    CADENT THERAPEUTICS, INC.
    12/30/19
  376. 75
    Positive allosteric modulators of the muscarinic acetylcholine receptor M4
    Vanderbilt University
    12/30/19
  377. 25
    RIPK2 inhibitors and method of treating cancer with same
    University Health Network
    12/30/19
  378. 86
    Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors
    Dart NeuroScience (Cayman) Ltd
    12/30/19
  379. 243
    Sulfonamide compounds as voltage-gated sodium channel modulators
    LUPIN LIMITED
    12/30/19
  380. 58
    Therapeutic compounds and uses thereof
    Genetech, Inc
    12/30/19
  381. 169
    Triaza-spirodecanones as DDR1 inhibitors
    Hoffman-La Roche Inc
    12/30/19
  382. 240
    Triazole compounds as T-type calcium channel blockers
    IDORSIA PHARMACEUTICALS Ltd
    12/30/19
  383. 76
    Triterpenoids with HIV maturation inhibitory activity
    VIIV HEALTHCARE UK (NO. 4) LIMITED
    12/30/19
  384. 248
    Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
    Amgen Inc
    12/30/19
  385. 287
    3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
    Bayer Pharma Aktiengesellschaft
    12/27/19
  386. 57
    9-membered fused ring derivative
    Shionogi & Co., Ltd
    12/27/19
  387. 8
    Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
    Oryzon Genomics, S.A.
    12/27/19
  388. 45
    Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments
    University of California
    12/27/19
  389. 221
    CDK2/4/6 inhibitors
    Pfizer Inc
    12/27/19
  390. 650
    Compounds and methods for kinase modulation, and indications therefor
    Plexxikon Inc.
    12/27/19
  391. 159
    Compounds and their use as BACE inhibitors
    AstraZeneca AB
    12/27/19
  392. 49
    Compounds for use as GPR120 agonists
    Piramal Enterprises Limited
    12/27/19
  393. 130
    Compounds useful for treating disorders related to RET
    BLUEPRINT MEDICINES CORPORATION
    12/27/19
  394. 13
    Cystathionine-gamma-lyase (CSE) inhibitors
    SOVA PHARMACEUTICALS, INC.
    12/27/19
  395. 6
    Enantiomers of the 1′,6′-isomer of neplanocin A
    Auburn University
    12/27/19
  396. 8
    Estrogen receptor modulators and uses thereof
    Genentech Inc
    12/27/19
  397. 47
    Fused bicyclic compounds for the treatment of disease
    AKARNA THERAPEUTICS, LTD.
    12/27/19
  398. 76
    Fused pyrimidine compound or salt thereof
    Taiho Pharmaceutical Co., Ltd
    12/27/19
  399. 6
    Ghrelin 0-acyl transferase inhibitors
    Eli Lilly and Company
    12/27/19
  400. 46
    Glucosylceramide synthase inhibitors for the treatment of diseases
    BioMarin Pharmaceutical Inc
    12/27/19
  401. 99
    Heteroaryl compounds for kinase inhibition
    ARIAD Pharmaceuticals Inc
    12/27/19
  402. 337
    Heterocyclic modulators of lipid synthesis and combinations thereof
    3-V Biosciences, Inc.
    12/27/19
  403. 21
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    12/27/19
  404. 157
    IDO inhibitors
    NewLink Genetics Corporation
    12/27/19
  405. 145
    Inhibiting agents for bruton's tyrosine kinase
    BIOGEN MA INC.
    12/27/19
  406. 11
    Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety
    Universitetet | Oslo
    12/27/19
  407. 109
    Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
    Vanderbilt University
    12/27/19
  408. 158
    LSD1 inhibitors
    Mirati Therapeutics Inc
    12/27/19
  409. 369
    Metallo-β-lactamase inhibitors
    Merck Sharp & Dohme Corp
    12/27/19
  410. 39
    Methods for treating depressive symptoms
    ALKERMES PHARMA IRELAND LIMITED
    12/27/19
  411. 104
    Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof
    Pfizer Inc
    12/27/19
  412. 129
    Phosphatidylinositol 3-kinase inhibitors
    Gilead Sciences Inc
    12/27/19
  413. 16
    Pyrazole orexin receptor antagonists
    Merck Sharp & Dohme Corp
    12/27/19
  414. 24
    Selective histone deactylase 6 inhibitors
    H. Lee Moffitt Cancer Center and Research Institute Inc
    12/27/19
  415. 75
    Small molecule NF-κB inhibitors
    ImmuneTarget, Inc.
    12/27/19
  416. 642
    Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
    Janssen Pharmaceutica NV
    12/27/19
  417. 136
    Substituted benzenesulfonamides as sodium channel blockers
    Daewoong Pharmaceutical Co., Ltd.
    12/27/19
  418. 75
    Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors
    Merck Patent GmbH
    12/27/19
  419. 244
    Substituted spirocyclic inhibitors of autotaxin
    X-Rx, Inc.
    12/27/19
  420. 4
    T-type calcium channel modulator and uses thereof
    UTI LIMITED PARTNERSHIP
    12/27/19
  421. 25
    TRPV1 vanilloid receptor antagonists with a bicyclic portion
    TBA
    12/27/19
  422. 26
    Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
    Bristol-Myers Squibb Company
    12/27/19
  423. 28
    Tricyclic heterocycles as bet protein inhibitors
    Incyte Corporation
    12/27/19
  424. 292
    Compounds useful as immunomodulators
    Bristol-Myers Squibb Company
    12/19/19
  425. 307
    Methods of treatment using pyridinonyl PDK1 inhibitors
    Sunesis Pharmaceuticals Inc
    12/19/19
  426. 43
    P2X4 receptor antagonist
    Nippon Chemiphar Co., Ltd
    12/19/19
  427. 774
    Triazolopyridine compounds, compositions and methods of use thereof
    Genentech Inc
    12/19/19
  428. 47
    Heterocycles as modulators of kinase activity
    Merck Patent GmbH
    12/12/19
  429. 72
    Pyridyl benzothiophenes as kinase inhibitors
    Allergan Inc
    12/12/19
  430. 92
    C-linked heterocycloaklyl substituted pyrimidines and their uses
    Genentech Inc
    12/10/19
  431. 51
    Diazine-fused amidines as BACE inhibitors, compositions, and their use
    Merck Sharp & Dohme Corp
    12/10/19
  432. 19
    Heteroaromatic compounds and their use as dopamine D1 ligands
    Pfizer Inc
    12/10/19
  433. 214
    Inhibitors of protein kinases
    Portola Pharmaceuticals Inc
    12/10/19
  434. 185
    Serine/threonine kinase inhibitors
    Genentech Inc
    12/10/19
  435. 110
    Thiazolopyrrolidine inhibitors of ROR- γ
    Vitae Pharmaceuticals Inc
    12/10/19
  436. 7
    Hydrophobically tagged janus kinase inhibitors and uses thereof
    Dana-Farber Cancer Institute Inc
    12/03/19
  437. 393
    Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
    Bristol-Myers Squibb Company
    12/03/19
  438. 7
    Indolyl-containing RORγt inhibitors
    ORCA PHARMACEUTICALS LIMITED
    12/03/19
  439. 20
    Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
    Purdue Pharma LP
    12/03/19
  440. 58
    Potent and selective inhibitors of monoamine transporters; method of making; and use thereof
    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH
    12/03/19
  441. 13
    Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
    Novartis AG
    12/03/19
  442. 13
    Tetrahydrocarboline derivative
    Ono Pharmaceutical Co., Ltd
    12/03/19
  443. 83
    TrkA kinase inhibitors, compositions and methods thereof
    Merck Sharp & Dohme Corp
    12/03/19
  444. 106
    2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase
    Cancer Therapeutics CRC Pty Ltd
    11/21/19
  445. 340
    Aminoquinazoline and pyridopyrimidine derivatives
    Genentech Inc
    11/21/19
  446. 38
    Carboxylic acid compound, method for preparation thereof, and use thereof
    InventisBio Shanghai Ltd.
    11/21/19
  447. 39
    Heteroaromatic compounds and their use as dopamine D1 ligands
    Pfizer Inc
    11/21/19
  448. 124
    Inhibitor compounds of phosphodiesterase type 10A
    AbbVie Deutschland GmbH & Co. KG
    11/21/19
  449. 68
    Pyrazolonaphthyridinone derivatives as MetAP2 inhibitors (methionine aminopeptidase type-2)
    Sanofi
    11/21/19
  450. 42
    Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors
    Sunovion Pharmaceuticals Inc
    11/21/19
  451. 57
    Substituted tropane derivatives
    Toa Eiyo Ltd
    11/21/19
  452. 11
    Treatment of respiratory disorders using ROR-gamma inhibitors
    GLENMARK PHARMACEUTICALS S.A.
    11/21/19
  453. 5
    1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties
    The Regents of the University of Michigan
    11/14/19
  454. 122
    Autotaxin inhibitor compounds
    PharmAkea Inc
    11/14/19
  455. 375
    Compounds useful as immunomodulators
    Bristol-Myers Squibb Company
    11/14/19
  456. 151
    Cycloalkane derivatives
    Daiichi Sankyo Company, Limited
    11/14/19
  457. 21
    Inhibitors of the renal outer medullary potassium channel
    Merck Sharp & Dohme Corp
    11/14/19
  458. 485
    Intermediates for preparing triazole agonists of the APJ receptor
    Amgen Inc
    11/14/19
  459. 62
    Isoindoline inhibitors of ROR-gamma
    Vitae Pharmaceuticals Inc
    11/14/19
  460. 10
    Pyrazolopyridyl compounds as aldosterone synthase inhibitors
    Merck Sharp & Dohme Corp
    11/14/19
  461. 27
    SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors
    Indiana University Research and Technology Corporation
    11/14/19
  462. 47
    Substituted 2-azabicycles and their use as orexin receptor modulators
    TBA
    11/14/19
  463. 43
    Substituted tetrahydrocarbazole and carbazole carboxamide compounds
    Bristol-Myers Squibb Company
    11/14/19
  464. 207
    Therapeutically active compositions and their methods of use
    Agios Pharmaceuticals Inc
    11/14/19
  465. 13
    Tricyclic heterocycles as BET protein inhibitors
    Incyte Corporation
    11/14/19
  466. 10
    Heterocyclic compounds and uses thereof
    Incyte Corporation
    10/31/19
  467. 121
    Morpholin-pyridine derivatives
    Hoffmann-La Roche Inc
    10/31/19
  468. 18
    N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
    OGED SA
    10/31/19
  469. 32
    Substituted quinazolin-4-one derivatives
    Novartis AG
    10/31/19
  470. 41
    BTK inhibitors
    Merck Sharp & Dohme Corp
    10/28/19
  471. 125
    Benzylamine derivatives
    Kalvista Pharmceuticals Limited
    10/28/19
  472. 12
    Indazoles and use thereof
    Purdue Pharma LP
    10/28/19
  473. 14
    Piperidinone carboxamide azaindane CGRP receptor antagonists
    Merck Sharp & Dohme Corp
    10/28/19
  474. 129
    Pyridazine compounds as JAK inhibitors
    Portola Pharmaceuticals Inc
    10/28/19
  475. 109
    Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors
    ARRIEN PHARMACEUTICALS LLC
    10/28/19
  476. 209
    Substituted quinolines as PDE-10 inhibitors
    Sunovion Pharmaceuticals Inc
    10/28/19
  477. 13
    Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
    vTv Therapeutics LLC
    10/28/19
  478. 29
    Tricyclic heterocycles as bet protein inhibitors
    Incyte Corporation
    10/28/19
  479. 19
    3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
    Rugen Holdings (Cayman) Limited
    10/27/19
  480. 64
    Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
    Vanderbilt University
    10/27/19
  481. 159
    Chemical compounds
    AstraZeneca AB
    10/27/19
  482. 248
    Inhibiting the transient receptor potential A1 ion channel
    Hydra Biosciences Inc
    10/27/19
  483. 492
    Metallo-beta-lactamase inhibitors
    Merck Sharp & Dohme Corp
    10/27/19
  484. 22
    N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors
    The Regents of the University of Michigan
    10/27/19
  485. 147
    Phosphatidylinositol 3-kinase inhibitors
    Gilead Sciences Inc
    10/27/19
  486. 82
    Purine inhibitors of human phosphatidylinositol 3-kinase delta
    Merck Sharp & Dohme Corp
    10/27/19
  487. 44
    Pyridine compounds
    Daiichi Sankyo Company, Limited
    10/27/19
  488. 25
    Pyridinecarboxamides as CXCR2 modulators
    Syntrix Biosystems, Inc.
    10/27/19
  489. 42
    Substituted pyrrolo[3,4-e]indolizines, imidazo[1,2-a]pyrrolo[3,4-e]pyridines, pyrrolo[3,4-e][1,2,4]triazolo[1,5-a]pyridines and pyrrolo[3,4-e][1,2,4]triazolo[4,3-a]pyridines as positive allosteric modulators of muscarinic acetylcholine receptor M1
    Vanderbilt University
    10/27/19
  490. 64
    Oxazole orexin receptor antagonists
    Merck Sharp & Dohme Corp
    10/24/19
  491. 92
    Alkyne compounds for treatment of complement mediated disorders
    Achillion Pharmaceuticals Inc
    10/22/19
  492. 10
    Benzimidazole derivatives and use thereof
    Purdue Pharma LP
    10/22/19
  493. 224
    Biphenyl derivatives and methods for preparing same
    DONG-A ST CO., LTD
    10/22/19
  494. 93
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    10/22/19
  495. 166
    Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
    Merck Sharpe & Dohme Corp.
    10/22/19
  496. 69
    Kinase inhibitors and methods of use
    Intellikine LLC
    10/22/19
  497. 47
    Substituted pyrazino[2,2-a]isoquinoline derivatives
    Hoffmann-La Roche Inc
    10/22/19
  498. 88
    Substituted pyrazolopyrimidines and method of use
    AbbVie Deutschland GmbH & Co. KG
    10/22/19
  499. 56
    (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
    Oryzon Genomics, S.A.
    10/20/19
  500. 19
    2-heteroaryl carboxamides
    Bayer Intellectual Property GmbH
    10/20/19
  501. 14
    5-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
    ViiV HEALTHCARE UK (NO. 5) LIMITED
    10/20/19
  502. 11
    Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof
    TBA
    10/20/19
  503. 18
    Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
    Bayer Pharma Aktiengesellschaft
    10/20/19
  504. 18
    Amino-substituted heterocyclic derivatives as sodium channel inhibitors
    Almirall, S.A.
    10/20/19
  505. 76
    Amlexanox analogs
    The Regents of the University of Michigan
    10/20/19
  506. 85
    Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
    Incyte Corporation
    10/20/19
  507. 774
    Bicyclic heteroaryl amine compounds
    Bristol-Myers Squibb Company
    10/20/19
  508. 37
    Bicyclic heterocycles as FGFR4 inhibitors
    Incyte Corporation
    10/20/19
  509. 174
    Btk inhibitors
    Merck Sharp & Dohme Corp
    10/20/19
  510. 137
    Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators
    Reset Therapeutics, Inc.
    10/20/19
  511. 97
    Compositions and methods for treating ocular diseases
    Aerpio Therapeutics Inc
    10/20/19
  512. 9
    Compounds and methods for inhibiting production of trimethylamine
    The Procter & Gamble Company
    10/20/19
  513. 9
    Compounds, compositions and methods useful for cholesterol mobilization
    Cerenis Therapeutics Holding SA
    10/20/19
  514. 94
    Dihydropyridinone MGAT2 inhibitors
    Bristol-Myers Squibb Company
    10/20/19
  515. 227
    Factor XIA inhibitors
    Merck Sharp & Dohme Corp
    10/20/19
  516. 238
    Heterocyclic inhibitors of MCT4
    Vettore, LLC
    10/20/19
  517. 16
    Hydroxmethyl piperidine orexin receptor antagonists
    Merck Sharp & Dohme Corp
    10/20/19
  518. 154
    Imidazopyridazine and imidazothiadiazole compounds
    Universite de Montreal
    10/20/19
  519. 13
    Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments
    University of California
    10/20/19
  520. 288
    Inhibitors of human immunodeficiency virus replication
    ViiV HEALTHCARE UK (NO. 5) LIMITED
    10/20/19
  521. 92
    Inhibitors of lysine methyl transferase
    Bristol-Myers Squibb Company
    10/20/19
  522. 94
    Inhibitors of plasma kallikrein
    Kalvista Pharmaceuticals Limited
    10/20/19
  523. 4
    Metalloenzyme inhibitor compounds
    Mycovia Pharmaceuticals, Inc.
    10/20/19
  524. 88
    Method of treating conditions with kinase inhibitors
    Allergan Inc
    10/20/19
  525. 7
    N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
    Ogeda SA
    10/20/19
  526. 10
    Pharmaceutical formulations comprising CCR3 antagonists
    Alkahest, Inc.
    10/20/19
  527. 327
    Phosphatidylinositol 3-kinase inhibitors
    Gilead Sciences Inc
    10/20/19
  528. 32
    Protein kinase inhibitors
    Pharmascience Inc
    10/20/19
  529. 6
    Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
    Arena Pharmaceuticals Inc
    10/20/19
  530. 6
    Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
    ViiV HEALTHCARE UK (NO. 5) LIMITED
    10/20/19
  531. 3
    Quinazolines as potassium ion channel inhibitors
    Bristol-Myers Squibb Company
    10/20/19
  532. 370
    Solid dispersions containing an apoptosis-inducing agent
    AbbVie Inc
    10/20/19
  533. 44
    Substituted 2-phenyl (AZA)benzofuran compounds for the treatment of hepatitis C
    Bristol-Myers Squibb Company
    10/20/19
  534. 11
    Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments
    University of Chicago
    10/20/19
  535. 107
    Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
    Incyte Corporation
    10/20/19
  536. 143
    Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
    Bayer Pharma Aktiengesellschaft
    10/20/19
  537. 118
    Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
    Merck Sharp & Dohme Corp
    10/20/19
  538. 9
    Substituted pyrazoles as inhibitors of fibroblast growth factor receptor
    Zhejiang Hisun Pharmaceutical Co., Ltd
    10/20/19
  539. 411
    Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
    Lycera Corporation
    10/20/19
  540. 507
    Triazole agonists of the APJ receptor
    Amgen Inc
    10/20/19
  541. 65
    Triazolopyridine inhibitors of myeloperoxidase
    Bristol-Myers Squibb Company
    10/20/19
  542. 57
    Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
    MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
    10/20/19
  543. 255
    Compounds, compositions and methods
    Denali Therapeutics Inc.
    10/14/19
  544. 33
    Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof
    Merck Patent GmbH
    10/14/19
  545. 24
    Protein kinase inhibitor containing pyrrolopyridazine derivative
    The Asan Foundation
    10/14/19
  546. 126
    Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors
    Novartis AG
    10/14/19
  547. 12
    Selective glycosidase inhibitors and uses thereof
    Alectos Therapeutics Inc
    10/14/19
  548. 227
    TrkA kinase inhibitors, compositions and methods thereof
    Merck Sharp & Dohme Corp
    10/14/19
  549. 92
    Azabenzimidazole compounds
    Pfizer Inc
    10/13/19
  550. 23
    Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
    Janssen Pharmaceutica NV
    10/13/19
  551. 76
    Complement pathway modulators and uses thereof
    Novartis AG
    10/13/19
  552. 7
    Liver X receptor modulators
    Vitae Pharamceuticals, Inc.
    10/13/19
  553. 689
    Pyrimidone carboxamide compounds as PDE2 inhibitors
    Merck Sharp & Dohme Corp
    10/13/19
  554. 91
    Quinolone derivatives as fibroblast growth factor receptor inhibitors
    Principia Biopharma Inc
    10/13/19
  555. 7
    Rho kinase inhibitors
    Kadmon Corporation LLC
    10/13/19
  556. 166
    Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors
    The University of Rochester
    10/13/19
  557. 24
    Aminoester derivatives
    Chiesi Farmaceutici S.p.A.
    10/07/19
  558. 7
    Compounds inhibiting leucine-rich repeat kinase enzyme activity
    Merck Sharp & Dohme Corp
    10/07/19
  559. 1
    Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds
    Suzhou Zelgen Biopharmaceuticals Co., Ltd.
    10/07/19
  560. 30
    Factor IXa inhibitors
    Merck Sharp & Dohme Corp
    10/07/19
  561. 25
    Factor XIa inhibitors
    Merck Sharp & Dohme Corp
    10/07/19
  562. 248
    Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
    Les Laboratoires Servier
    10/07/19
  563. 31
    Oxazolidine-based compound and selective androgen receptor agonist comprising same
    DONG-A ST CO., LTD
    10/07/19
  564. 422
    Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
    Merck Sharp & Dohme Corp
    10/07/19
  565. 44
    2-aryl selenazole compound and pharmaceutical composition thereof
    JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.
    10/01/19
  566. 9
    3-oxo-tetrahydro-furo[3,2-b]pyrrol-4(5H)-yl) derivatives II
    GRÜNENTHAL GMBH
    10/01/19
  567. 43
    5-hydroxytryptamine receptor 7 activity modulators and their method of use
    TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    10/01/19
  568. 34
    Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
    Hoffmann-La Roche Inc
    10/01/19
  569. 37
    Bicyclic heterocycles as FGFR4 inhibitors
    Incyte Corporation
    10/01/19
  570. 24
    C-6 spirocarbocyclic iminothiadiazine dioxides as BACE inhibitors, compositions, and their use
    Merck Sharp & Dohme Corp
    10/01/19
  571. 476
    Heteroaryls and uses thereof
    Millennium Pharmaceuticals Inc
    10/01/19
  572. 23
    Imidazopyridazine derivatives as modulators of the GABAA receptor activity
    Pfizer Limited
    10/01/19
  573. 215
    Indole carboxamide compounds
    Bristol-Myers Squibb Company
    10/01/19
  574. 20
    Inhibitors of bruton's tyrosine kinase
    Hoffman-La Roche Inc
    10/01/19
  575. 62
    Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
    The United States of America, as represented by the Secretary, Department of Health and Human Services
    10/01/19
  576. 77
    Macrocycles as factor XIa inhibitors
    Bristol-Myers Squibb Company
    10/01/19
  577. 107
    Pyridineamine compounds useful as Pim kinase inhibitors
    Incyte Corporation
    10/01/19
  578. 34
    Pyridinyl and fused pyridinyl triazolone derivatives
    Takeda Pharmaceutical Company Limited
    10/01/19
  579. 129
    Pyrimidine compounds as mTOR and PI3K inhibitors
    Development Center for Biotechnology
    10/01/19
  580. 32
    Quinoline derivatives as PDE10A enzyme inhibitors
    H. Lundbeck A/S
    10/01/19
  581. 219
    Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
    Galapagos NV
    09/24/19
  582. 167
    Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
    Achillion Pharmaceuticals Inc
    09/23/19
  583. 11
    Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
    BioMarin Pharmaceutical Inc
    09/23/19
  584. 33
    Compounds as diacylglycerol acyltransferase inhibitors
    GlaxoSmithKline LLC
    09/23/19
  585. 44
    Dihydropyrrolopyridine inhibitors of ROR-gamma
    Vitae Pharmaceuticals Inc
    09/23/19
  586. 23
    Dihydroquinoline pyrazolyl compounds
    Hoffmann-La Roche Inc
    09/23/19
  587. 344
    ERK inhibitors and uses thereof
    Celgene CAR LLC
    09/23/19
  588. 31
    Glucocerebrosidase modulators and uses thereof
    Alectos Therapeutics Inc
    09/23/19
  589. 31
    Imidazole-derived modulators of the glucocorticoid receptor
    Bristol-Myers Squibb Company
    09/23/19
  590. 173
    Inhibitors of Jun N-terminal kinase
    Imago Pharmaceuticals Inc
    09/23/19
  591. 93
    Isoindoline compositions and methods for treating neurodegenerative disease
    COGNITION THERAPEUTICS, INC.
    09/23/19
  592. 61
    Kinase inhibitors
    Respivert Limited
    09/23/19
  593. 59
    Method of treatment using substituted imidazo[1,2b]pyridazine compounds
    Array BioPharma Inc
    09/23/19
  594. 60
    Method of treatment using substituted imidazo[1,2b]pyridazine compounds
    Array BioPharma Inc
    09/23/19
  595. 36
    Piperazine derivatives for treating disorders
    The University of Nottingham
    09/23/19
  596. 9
    Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
    Gilead Sciences Inc
    09/23/19
  597. 15
    Protein kinase inhibitors
    Pharmascience Inc
    09/23/19
  598. 122
    Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
    Millennium Pharmaceuticals Inc
    09/23/19
  599. 42
    Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof
    SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    09/23/19
  600. 1352
    Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors
    AbbVie Inc
    09/23/19
  601. 35
    Pyrrolopyrimidine compounds for the treatment of cancer
    The University of North Carolina at Chapel Hill
    09/23/19
  602. 18
    S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by PDE7
    Consejo Superior de Investigaciones Cientificas
    09/23/19
  603. 124
    Selective inhibitors of Tec and Src protein kinase families
    Pharmascience Inc
    09/23/19
  604. 232
    Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
    Array BioPharma Inc
    09/23/19
  605. 275
    Substituted quinazolines as receptor-type kinase inhibitors
    SYMPHONY EVOLUTION, INC.
    09/23/19
  606. 23
    1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
    Takeda Pharmaceutical Company Limited
    09/21/19
  607. 83
    2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
    Array BioPharma Inc
    09/21/19
  608. 3
    ACC inhibitors and uses thereof
    GILEAD APOLLO, LLC
    09/21/19
  609. 25
    Benzothiophene estrogen receptor modulators
    G1 Therapeutics, Inc.
    09/21/19
  610. 133
    Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
    Enanta Pharmaceuticals Inc
    09/21/19
  611. 322
    Compounds useful for the treatment of degenerative and inflammatory diseases
    Galapagos NV
    09/21/19
  612. 97
    Condensed tricyclic compounds as protein kinase inhibitors
    FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.P. CNIO)
    09/21/19
  613. 19
    Eis inhibitors
    University of Kentucky Research Foundation
    09/21/19
  614. 11
    Fused imidazo-piperidine JAK inhibitors
    THERAVANCE BIOPHARMA R&D IP, LLC
    09/21/19
  615. 246
    GLP-1 receptor agonists and uses thereof
    Pfizer Inc
    09/21/19
  616. 7
    Heterocyclic inhibitors of the sodium channel
    TBA
    09/21/19
  617. 146
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    09/21/19
  618. 68
    Imidazopyridazine compounds and their use
    Hutchison MediPharma Limited
    09/21/19
  619. 10
    Inhibitors of HIF prolyl hydroxylase
    Merck Sharp & Dohme Corp
    09/21/19
  620. 119
    Inhibitors of lysine specific demethylase-1
    Celgene Quanticel Research Inc
    09/21/19
  621. 36
    Inhibitors of the renal outer medullary potassium channel
    WuXi AppTec (Shanghai) Co. Ltd
    09/21/19
  622. 93
    Isoindoline compositions and methods for treating neurodegenerative disease
    COGNITION THERAPEUTICS, INC.
    09/21/19
  623. 46
    Macrocycles as factor XIa inhibitors
    Bristol-Myers Squibb Company
    09/21/19
  624. 31
    Methods for inhibiting fascin
    Cornell University
    09/21/19
  625. 1
    Processes for preparing ATR inhibitors
    Vertex Pharmaceuticals Incorporated
    09/21/19
  626. 62
    Substituted amino triazoles useful as human chitinase inhibitors
    OncoArendi Therapeutics SA
    09/21/19
  627. 21
    Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
    Bristol-Myers Squibb Company
    09/21/19
  628. 35
    Tertiary alcohol imidazopyrazine BTK inhibitors
    Merck Sharp & Dohme Corp
    09/21/19
  629. 311
    Therapeutic compounds and uses thereof
    Genentech Inc
    09/21/19
  630. 187
    Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
    Allergan Inc
    09/21/19
  631. 21
    1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
    Incyte Holdings Corporation
    09/09/19
  632. 106
    2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives
    Hoffmann-La Roche Inc
    09/09/19
  633. 356
    Bruton's tyrosine kinase inhibitors
    Sunesis Pharmaceuticals Inc
    09/09/19
  634. 19
    Compositions and methods of modulating 15-PGDH activity
    Case Western Reserve University
    09/09/19
  635. 91
    Compositions and methods of modulating short-chain dehydrogenase activity
    Case Western Reserve University
    09/09/19
  636. 45
    Compounds as rearranged during transfection (RET) inhibitors
    GlaxoSmithKline Intellectual Property Development Limited
    09/09/19
  637. 55
    Diacylglycerol acyltransferase 2 inhibitors
    Pfizer Inc
    09/09/19
  638. 72
    Enhancer of zeste homolog 2 inhibitors
    GlaxoSmithKline Intellectual Property (No. 2) Limited
    09/09/19
  639. 287
    Heteroaryl compounds as IRAK inhibitors and uses thereof
    Merck Patent GmbH
    09/09/19
  640. 194
    Heterocyclic kinase inhibitors
    Intellikine LLC
    09/09/19
  641. 25
    Inhibitor compounds of phosphodiesterase type 10A
    AbbVie Inc
    09/09/19
  642. 118
    Kinase inhibitors
    Respivert Limited
    09/09/19
  643. 17
    Kinase inhibitors
    Respivert Limited
    09/09/19
  644. 4
    Lysine demethylase inhibitors for diseases and disorders associated with Flaviviridae
    Oryzon Genomics, S.A.
    09/09/19
  645. 130
    MK2 inhibitors and uses thereof
    Celgene CAR LLC
    09/09/19
  646. 10
    Methods of identifying SENP1 inhibitors
    City of Hope
    09/09/19
  647. 113
    Piperidine and azepine derivatives as prokineticin receptor modulators
    Takeda Pharmaceutical Company Limited
    09/09/19
  648. 41
    Piperidine derivatives as HDAC1/2 inhibitors
    REGENACY PHARMACEUTICALS, LLC
    09/09/19
  649. 85
    Pyridinyloxy- and phenyloxy-pyrazolyl compounds
    Hoffmann-La Roche Inc
    09/09/19
  650. 20
    Somatostatin receptor subtype 4 (SSTR4) agonists
    Centrexion Therapeutics Corporation
    09/09/19
  651. 98
    Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
    Janssen Pharmaceutica NV
    09/09/19
  652. 25
    Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
    Takeda Pharmaceutical Company Limited
    09/09/19
  653. 12
    Substituted tropolone derivatives and methods of use
    University of Connecticut
    09/09/19
  654. 16
    β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
    Atea Pharmaceuticals, Inc.
    09/02/19
  655. 393
    1,3-thiazol-2-yl substituted benzamides
    Bayer Aktiengesellschaft
    09/02/19
  656. 39
    2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
    BLUEPRINT MEDICINES CORPORATION
    09/02/19
  657. 15
    3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
    IDENIX PHARMACEUTICALS LLC
    09/02/19
  658. 115
    3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
    Samumed, LLC
    09/02/19
  659. 46
    8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
    Boehringer Ingelheim International GmbH
    09/02/19
  660. 153
    Benzimidazole derivatives as selective proteine kinase inhibitors
    AB SCIENCE
    09/02/19
  661. 88
    CXCR7 receptor modulators
    IDORSIA PHARMACEUTICALS Ltd
    09/02/19
  662. 34
    Dihydroxy aromatic heterocyclic compound
    Takeda Pharmaceutical Company Limited
    09/02/19
  663. 43
    Fused-ring compounds, pharmaceutical composition and uses thereof
    Shanghai De Novo Pharmatech Co., Ltd
    09/02/19
  664. 28
    Heteroaryl substituted aminopyridine compounds
    Bristol-Myers Squibb Company
    09/02/19
  665. 49
    Heteroaryls and uses thereof
    Millennium Pharmaceuticals Inc
    09/02/19
  666. 62
    Heterocyclic compounds and methods of use thereof
    The United States of America, as represented by the Secretary, Department of Health and Human Services
    09/02/19
  667. 145
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    09/02/19
  668. 20
    Hydroxy-ethylene derivatives for the treatment of arthrosis
    Merck Patent GmbH
    09/02/19
  669. 2
    Inhibitors of leukotriene A4 hydrolase
    Celtaxsys, Inc.
    09/02/19
  670. 81
    MCT4 inhibitors for treating disease
    Vettore, LLC
    09/02/19
  671. 18
    Macrocyclic benzofuran compounds for the treatment of hepatitis C
    Bristol-Myers Squibb Company
    09/02/19
  672. 26
    N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors
    Redx Pharma PLC
    09/02/19
  673. 19
    Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors
    Novartis AG
    09/02/19
  674. 127
    Polycyclic pyridone derivative having integrase inhibitory activity
    Shionogi & Co., Ltd
    09/02/19
  675. 120
    Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
    Millennium Pharmaceuticals Inc
    09/02/19
  676. 388
    Substituted polycyclic carbamoyl pyridone derivative prodrug
    Shionogi & Co., Ltd
    09/02/19
  677. 361
    Therapeutic compounds
    Celgene Quanticel Research Inc
    09/02/19
  678. 120
    Therapeutic compounds and uses thereof
    Genentech Inc
    09/02/19
  679. 200
    Therapeutic compounds and uses thereof
    Genentech Inc
    09/02/19
  680. 107
    Histone deacetylase inhibitors and compositions and methods of use thereof
    CHDI Foundation Inc
    08/20/19
  681. 80
    Substituted quinolines as modulators of sodium channels
    Vertex Pharmaceuticals Incorporated
    08/20/19
  682. 19
    Aminoimidazopyridazines
    Bayer Pharma Aktiengesellschaft
    08/19/19
  683. 40
    Factor Xla inhibitors
    Merck Sharp & Dohme Corp
    08/19/19
  684. 66
    IAP antagonists
    Bristol-Myers Squibb Company
    08/19/19
  685. 356
    Indazole ureas and method of use
    AbbVie Inc
    08/19/19
  686. 22
    Kinase inhibitors
    Respivert Limited
    08/19/19
  687. 10
    Protein tyrosine kinase modulators and methods of use
    Betta Pharmaceuticals Co., Ltd
    08/19/19
  688. 9
    Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
    Glaceum Inc.
    08/19/19
  689. 255
    Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
    Lycera Corporation
    08/18/19
  690. 18
    2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition
    Northwestern University
    08/17/19
  691. 24
    Quinoline derivatives and their applications
    Shenyang Pharmaceutical University
    08/17/19
  692. 232
    Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
    Array BioPharma Inc
    08/17/19
  693. 33
    Amino-substituted imidazopyridazines
    Bayer Intellectual Property GmbH
    08/13/19
  694. 185
    Furo-3-carboxamide derivatives and methods of use
    AbbVie Inc
    08/13/19
  695. 306
    PRMT5 inhibitors and uses thereof
    Epizyme Inc
    08/13/19
  696. 111
    Substituted 4-phenylpiperidines, their preparation and use
    Columbia University
    08/13/19
  697. 90
    Tricyclic fused thiophene derivatives as JAK inhibitors
    Incyte Holdings Corporation
    08/13/19
  698. 366
    Bicyclic sulfonamide compounds as sodium channel inhibitors
    Amgen Inc
    08/12/19
  699. 73
    Isoindolone derivatives
    AbbVie Inc
    08/12/19
  700. 158
    Pyrazole derivative
    Mochida Pharmaceutical Co., Ltd
    08/12/19
  701. 206
    Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase
    Sanofi
    08/12/19
  702. 269
    Tricyclic heterocycles as bet protein inhibitors
    Incyte Corporation
    08/12/19
  703. 41
    2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
    Merck Sharp & Dohme Corp
    08/11/19
  704. 109
    Heterocyclic compounds and uses thereof
    Infinity Pharmaceuticals Inc
    08/11/19
  705. 119
    Inhibitors of lysine specific demethylase-1
    Celgene Quanticel Research Inc
    08/11/19
  706. 8
    Pyrazolylbenzo[d]imidazole derivatives
    Celon Pharma S.A.
    08/11/19
  707. 253
    Compounds and methods for kinase modulation, and indications therefor
    Plexxikon Inc.
    08/06/19
  708. 156
    Indazole compounds useful as ketohexokinase inhibitors
    Janssen Pharmaceutica NV
    08/06/19
  709. 14
    Kinase inhibitors based upon N-alkyl pyrazoles
    Topivert Pharma Limited
    08/06/19
  710. 28
    N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides
    Pfizer Inc
    08/06/19
  711. 51
    N-substituted benzamides and methods of use thereof
    Genentech Inc
    08/06/19
  712. 33
    Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II
    Medifron DBT Inc.
    08/06/19
  713. 20
    Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors
    PHOENIX MOLECULAR DESIGN
    08/06/19
  714. 293
    Carbocyclic sulfone RORγ modulators
    Bristol-Myers Squibb Company
    08/05/19
  715. 119
    Inhibitors of lysine specific demethylase-1
    Celgene Quanticel Research Inc
    08/05/19
  716. 17
    Phenoxyalkylamine compound
    Osaka University
    08/02/19
  717. 308
    Therapeutic compounds and uses thereof
    Genentech Inc
    07/30/19
  718. 14
    3-ester-4 substituted orexin receptor antagonists
    Merck Sharp & Dohme Corp
    07/29/19
  719. 136
    Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
    University of Washington Through its Center for Commercialization
    07/29/19
  720. 23
    Heteroaryl compounds and uses thereof
    Celgene CAR LLC
    07/29/19
  721. 74
    Histone deacetylase inhibitors and compositions and methods of use thereof
    CHDI Foundation Inc
    07/29/19
  722. 173
    Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
    Les Laboratoires Servier
    07/29/19
  723. 193
    PRMT5 inhibitors and uses thereof
    Epizyme Inc
    07/29/19
  724. 113
    Phosphatidylinositol 3-kinase inhibitors
    Gilead Sciences Inc
    07/29/19
  725. 37
    Pyridine compounds as sodium channel blockers
    Purdue Pharma LP
    07/29/19
  726. 19
    Substituted benzylpyrazoles
    Bayer Pharma Aktiengesellschaft
    07/29/19
  727. 39
    Substituted oxopyridine derivatives
    Bayer Pharma Aktiengesellschaft
    07/29/19
  728. 15
    Therapeutic agent for pain
    Astellas Pharma Inc
    07/29/19
  729. 442
    Tricyclic piperidine compounds
    Actelion Pharmaceuticals Ltd
    07/29/19
  730. 201
    Autotaxin inhibitors
    Novartis AG
    07/26/19
  731. 263
    Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
    Novartis AG
    07/26/19
  732. 65
    IDO inhibitors
    Bristol-Myers Squibb Company
    07/26/19
  733. 43
    Trk-inhibiting compound
    Ono Pharmaceutical Co., Ltd
    07/26/19
  734. 44
    1-(cycloalkyl-carbonyl)proline derivative
    Sumitomo Dainippon Pharma Co., Ltd
    07/22/19
  735. 11
    2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same
    CrystalGenomics, Inc.
    07/22/19
  736. 35
    3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
    iTeos Therapeutics
    07/22/19
  737. 132
    4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
    Merck Sharp & Dohme B.V.
    07/22/19
  738. 67
    Aryl substituted indoles and the use thereof
    Purdue Pharma LP
    07/22/19
  739. 95
    Benzimidazole derivatives: preparation and pharmaceutical applications
    Mei Pharma Inc
    07/22/19
  740. 116
    Compounds for treatment of complement mediated disorders
    Achillion Pharmaceuticals Inc
    07/22/19
  741. 15
    Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
    Almirall, S.A.
    07/22/19
  742. 17
    Glucosylceramide synthase inhibitors and therapeutic methods using the same
    The Regents of the University of Michigan
    07/22/19
  743. 7
    Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
    Amgen Inc
    07/22/19
  744. 27
    Heterocyclic GSK-3 allosteric modulators
    Consejo Superior de Investigaciones Cientificas (CSIC)
    07/22/19
  745. 21
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    07/22/19
  746. 18
    Lysine specific demethylase-1 inhibitors and their use
    Oryzon Genomics, S.A.
    07/22/19
  747. 71
    Naphthyridine derivative compounds
    Astex Therapeutics Ltd
    07/22/19
  748. 159
    Pyridone amides as modulators of sodium channels
    Vertex Pharmaceuticals Incorporated
    07/22/19
  749. 153
    Pyrimidine derivatives
    Pfizer Inc
    07/22/19
  750. 362
    Quinolinyl modulators of RORγt
    Janssen Pharmaceutica NV
    07/22/19
  751. 102
    Styrenyl derivative compounds for treating ophthalmic diseases and disorders
    ACUCELA INC.
    07/22/19
  752. 350
    Therapeutic compounds and compositions
    Agios Pharmaceuticals Inc
    07/22/19
  753. 20
    Triazolopyridines and triazolopyrazines as LSD1 inhibitors
    Incyte Corporation
    07/22/19
  754. 10
    4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE)
    Janssen Pharmaceutica NV
    07/11/19
  755. 138
    Aryl sultam derivatives as RORc modulators
    Genentech Inc
    07/11/19
  756. 224
    Cyclopropanamine compound and use thereof
    Takeda Pharmaceutical Company Limited
    07/11/19
  757. 6
    Ethynyl derivatives
    Hoffmann-La Roche Inc
    07/11/19
  758. 477
    Heteroaryls and uses thereof
    Millennium Pharmaceuticals Inc
    07/11/19
  759. 58
    Heterocyclic compounds and uses thereof
    Infinity Pharmaceuticals Inc
    07/11/19
  760. 115
    Inhibitors of the renal outer medullary potassium channel
    Merck Sharp & Dohme Corp
    07/11/19
  761. 70
    Kinase inhibitors
    Respivert Limited
    07/11/19
  762. 47
    Macrocyclic compounds as Trk kinase inhibitors
    Array BioPharma Inc
    07/11/19
  763. 14
    Pyridazinones as DAAO enzyme inhibitors
    Takeda Pharmaceutical Company Limited
    07/11/19
  764. 21
    Selective histone deactylase 6 inhibitors
    H. Lee Moffitt Cancer Center and Research Institute Inc
    07/11/19
  765. 148
    Substituted uracils and use thereof
    Bayer Pharma Aktiengesellschaft
    07/11/19
  766. 11
    TRPA1 antagonists
    AbbVie Inc
    07/11/19
  767. 114
    2-amino 6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
    Pfizer Inc
    07/05/19
  768. 59
    2-pyridyloxy-4-ether orexin receptor antagonists
    Merck Sharp & Dohme Corp
    07/05/19
  769. 126
    4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof
    Merck Sharp & Dohme Corp
    07/05/19
  770. 62
    Aldosterone synthase inhibitors
    Boehringer Ingelheim International GmbH
    07/05/19
  771. 32
    Amidoimidazopyridazines as MKNK-1 kinase inhibitors
    Bayer Pharma Aktiengesellschaft
    07/05/19
  772. 20
    Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi
    PIRAMAL IMAGING SA
    07/05/19
  773. 45
    Compounds that are ERK inhibitors
    Merck Sharp & Dohme Corp
    07/05/19
  774. 885
    Flap modulators
    Janssen Pharmaceutica NV
    07/05/19
  775. 140
    Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
    Shanghai Yingli Pharmaceutical Co., Ltd
    07/05/19
  776. 23
    Heterocyclic compounds and their use as dopamine D1 ligands
    Pfizer Inc
    07/05/19
  777. 198
    Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
    SK Biopharmaceuticals Co. Ltd
    07/05/19
  778. 44
    Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use
    Merck Sharp & Dohme Corp
    07/05/19
  779. 47
    Indoline compounds as aldosterone synthase inhibitors
    Merck Sharp & Dohme Corp
    07/05/19
  780. 90
    Kallikrein 7 inhibitors
    SIXERA Pharma AB
    07/05/19
  781. 274
    PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
    Epizyme Inc
    07/05/19
  782. 286
    Pyrazolopyrimidine compounds for the treatment of cancer
    The University of North Carolina at Chapel Hill
    07/05/19
  783. 22
    Pyrimidines and use thereof
    Purdue Pharma LP
    07/05/19
  784. 89
    Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
    Incyte Corporation
    07/05/19
  785. 169
    Uracil derivatives as AXL and c-MET kinase inhibitors
    IGNYTA, INC.
    07/05/19
  786. 7
    Antagonists of prostaglandin EP3 receptor
    Pfizer Inc
    07/01/19
  787. 18
    Bicyclic heterocycles as bet protein inhibitors
    Incyte Corporation
    07/01/19
  788. 10
    Bicyclic inhibitors
    Kalvista Pharmaceuticals Limited
    07/01/19
  789. 24
    Compounds
    Astex Therapeutics Limited
    07/01/19
  790. 36
    Compounds as diacylglycerol acyltransferase inhibitors
    GlaxoSmithKline LLC
    07/01/19
  791. 93
    Histone demethylase inhibitors
    Celgene Quantical Research, Inc.
    07/01/19
  792. 16
    Inhibitors of lysine methyl transferase
    Bristol-Myers Squibb Company
    07/01/19
  793. 17
    NMDA receptor modulators and uses related thereto
    Emory University
    07/01/19
  794. 18
    Phenyl and benzodioxinyl substituted indazoles derivatives
    AstraZeneca AB
    07/01/19
  795. 9
    Phosphonate derivatives and methods of use thereof in the treatment of Alzheimer's disease
    University of Kansas
    07/01/19
  796. 111
    Pyrrolotriazine kinase inhibitors
    Bristol-Myers Squibb Company
    07/01/19
  797. 7
    Selected macrolides with PDE4-inhibiting activity
    Basilea Pharmaceutica AG
    07/01/19
  798. 17
    Small molecule activators of NRF2 pathway
    The General Hospital Corporation
    07/01/19
  799. 21
    Substituted 1H-indazol-1-OL analogs as inhibitors of beta catenin/Tcf protein-protein interactions
    University of Utah Research Foundation
    07/01/19
  800. 8
    Substituted benzamide derivatives as in vitro MAO-B inhibitors
    NTZ Lab Ltd
    07/01/19
  801. 379
    Tetrahydro-pyrimidoazepines as modulators of TRPV1
    Janssen Pharmaceutica NV
    07/01/19
  802. 318
    Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
    Bristol-Myers Squibb Company
    07/01/19
  803. 33
    Substituted aminoimidazopyridazines
    Bayer Intellectual Property GmbH
    06/26/19
  804. 43
    Ether compounds for treatment of complement mediated disorders
    Achillion Pharmaceuticals Inc
    06/24/19
  805. 21
    2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors
    Northwestern University
    06/23/19
  806. 555
    Aminotriazine derivative and pharmaceutical composition comprising the same
    Shionogi & Co., Ltd
    06/23/19
  807. 326
    Arylquinazolines
    Merck Patent GmbH
    06/23/19
  808. 990
    Benzimidazole-proline derivatives
    IDORSIA PHARMACEUTICALS Ltd
    06/23/19
  809. 39
    C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use
    Merck Sharp & Dohme Corp
    06/23/19
  810. 16
    Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
    Achillion Pharmaceuticals Inc
    06/23/19
  811. 38
    Cinnoline derivatives useful as CB-1 receptor inverse agonists
    Janssen Pharmaceutica NV
    06/23/19
  812. 30
    Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor
    Janssen Pharmaceutica NV
    06/23/19
  813. 353
    FLAP modulators
    Janssen Pharmaceutica NV
    06/23/19
  814. 237
    Heterocyclic derivative and pharmaceutical drug
    Nippon Shinyaku Co. Ltd
    06/23/19
  815. 326
    Heterocyclylamines as PI3K inhibitors
    Incyte Holdings Corporation
    06/23/19
  816. 72
    Kinase inhibitors
    Respivert Limited
    06/23/19
  817. 8
    N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use
    Galderma Research & Development
    06/23/19
  818. 29
    PRMT5 inhibitors and uses thereof
    Epizyme Inc
    06/23/19
  819. 26
    Process for the synthesis of a phosphoinositide 3-kinase inhibitor
    Incyte Corporation
    06/23/19
  820. 370
    Purine inhibitors of human phosphatidylinositol 3-kinase delta
    Merck Sharp & Dohme
    06/23/19
  821. 33
    Pyridinone and pyrimidinone derivatives as factor Xia
    Ono Pharmaceutical Co., Ltd
    06/23/19
  822. 67
    Pyrimidine FGFR4 inhibitors
    Eisai R&D Management Co., Ltd
    06/23/19
  823. 11
    Quinazoline derivatives substituted by aniline, preparation method and use thereof
    Xuanzhu Pharma Co., Ltd
    06/23/19
  824. 377
    RAF kinase modulator compounds and methods of use thereof
    Ambit Biosciences Corporation
    06/23/19
  825. 23
    Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
    Gilead Sciences Inc
    06/23/19
  826. 87
    Carbazole compounds useful as bromodomain inhibitors
    Bristol-Myers Squibb Company
    06/16/19
  827. 174
    Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof
    HANDOK INC.
    06/16/19
  828. 57
    Inhibitors of the fibroblast growth factor receptor
    BLUEPRINT MEDICINES CORPORATION
    06/16/19
  829. 6
    JAK inhibitors containing a 4-membered heterocyclic amide
    THERAVANCE BIOPHARMA R&D IP, LLC
    06/16/19
  830. 1
    MCL-1 inhibitors and methods of use thereof
    AstraZeneca AB
    06/16/19
  831. 233
    TYK2 inhibitors and uses thereof
    Nimbus Lakshmi, Inc.
    06/16/19
  832. 119
    Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection
    Hoffmann-La Roche Inc
    06/16/19
  833. 24
    1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as SGRM modulators
    AstraZeneca AB
    06/14/19
  834. 127
    4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof
    Merck Sharp & Dohme Corp
    06/14/19
  835. 41
    Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition containing the same, preparation method and use thereof
    SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD
    06/14/19
  836. 10
    Chemical compounds
    GlaxoSmithKline Intellectual Property (No. 2) Limited
    06/14/19
  837. 9
    Inhibitors of BCR-ABL mutants and use thereof
    The Regents of the University of Michigan
    06/14/19
  838. 11
    Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof
    ARROMAX PHARMATECH CO., LTD.
    06/14/19
  839. 102
    Spirocyclic EBI2 modulators
    Sanford Burnham Prebys Medical Discovery Institute
    06/14/19
  840. 86
    Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein
    THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    06/14/19
  841. 4
    Substituted quinazoline compounds and preparation and uses thereof
    Sunshine Lake Pharma Co., Ltd
    06/14/19
  842. 3
    Tetrahydropyranyl benzamide derivatives
    Eli Lilly and Company
    06/14/19
  843. 6
    bis-Pyridazine compounds and their use in treating cancer
    AstraZeneca AB
    06/14/19
  844. 32
    1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors
    Respivert Ltd
    06/12/19
  845. 89
    3-oxo-tetrahydro-furo[3,2-B]pyrrol-4(5H)-yl) derivatives I
    GRUNENTHAL GMBH
    06/12/19
  846. 15
    7-azaindole derivatives
    Merck Patent GmbH
    06/12/19
  847. 201
    Biaryl acetamide compounds and methods of use thereof
    Ambit Biosciences Corporation
    06/12/19
  848. 45
    CDK inhibitors
    G1 Therapeutics, Inc.
    06/12/19
  849. 38
    Carboxamide derivatives
    Novartis AG
    06/12/19
  850. 146
    Compounds as tyrosine kinase modulators
    Allergan Inc
    06/12/19
  851. 15
    Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents
    Duquesne University of the Holy Spirit
    06/12/19
  852. 296
    Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors
    Merck Sharp & Dohme Corp
    06/12/19
  853. 44
    Cystathionine-γ-lyase (CSE) inhibitors
    SOVA PHARMACEUTICALS, INC.
    06/12/19
  854. 17
    Cytochrome P450 inhibitors and their method of use
    CORTENDO AB (PUBL)
    06/12/19
  855. 91
    Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
    Nektar Therapeutics
    06/12/19
  856. 98
    GPR40 agonists in anti-diabetic drug combinations
    Janssen Pharmaceutica NV
    06/12/19
  857. 32
    Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
    Merck Sharp & Dohme Corp
    06/12/19
  858. 338
    Heterocyclic derivative having PGD2 receptor antagonist activity
    Shionogi & Co., Ltd
    06/12/19
  859. 99
    Highly selective sigma receptor ligands and radioligands as probes in nociceptive processing and the pathphysiological study of memory deficits and cognitive disorders
    The University of Mississippi
    06/12/19
  860. 93
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    06/12/19
  861. 31
    Hydroxy-substituted orexin receptor antagonists
    Merck Sharp & Dohme Corp
    06/12/19
  862. 3
    Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
    DeuteRx, LLC
    06/12/19
  863. 49
    N-substituted-5-substituted phthalamic acids as sortilin inhibitors
    H. Lundbeck A/S
    06/12/19
  864. 5
    Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
    Dartmouth College
    06/12/19
  865. 7
    Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
    Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    06/12/19
  866. 20
    Quinazoline derivative and preparation method therefor
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd
    06/12/19
  867. 31
    RORγ modulators
    Bristol-Myers Squibb Company
    06/12/19
  868. 16
    Substituted 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as factor XIa inhibitors
    Bristol-Myers Squibb Company
    06/12/19
  869. 26
    Substituted acethydrazide derivative, preparation method and use thereof
    Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    06/12/19
  870. 343
    Substituted pyrimidine compounds
    Gruenenthal GmbH
    06/12/19
  871. 292
    Tricyclic compounds as anticancer agents
    Bristol-Myers Squibb Company
    06/12/19
  872. 12
    Use of small molecule inhibitors targeting EYA tyrosine phosphatase
    CHILDREN HOSPITAL MEDICAL CENTER
    06/12/19
  873. 9
    [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof
    Santen Pharmaceutical Co., Ltd
    06/12/19
  874. 6
    γ-aminobutyric acid (GABA) analogues for the treatment of pain and other disorders
    Novassay S.A.
    06/04/19
  875. 28
    2 amino-3,4-dihydrcquinazoline derivatives and the use thereof as cathepsin D inhibitors
    Merck Patent GmbH
    06/04/19
  876. 573
    2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
    Lycera Corporation
    06/04/19
  877. 40
    3-aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof
    Merck Sharp & Dohme Corp
    06/04/19
  878. 18
    5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
    Cancer Research Technology Limited
    06/04/19
  879. 67
    5-oxa-2-azabicyclo[2.2.2]OCTAN-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives
    Hoffmann-La Roche Inc
    06/04/19
  880. 492
    AMPK-activating heterocyclic compounds and methods for using the same
    Rigel Pharmaceuticals, Inc
    06/04/19
  881. 113
    Aminopyrimidinyl compounds
    Pfizer Inc
    06/04/19
  882. 53
    Aromatic heterocyclic compounds and their application in pharmaceuticals
    Sunshine Lake Pharma Co., Ltd
    06/04/19
  883. 176
    Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
    Vitae Pharmaceuticals Inc
    06/04/19
  884. 56
    BET protein-inhibiting 5-aryltriazoleazepines
    Bayer Pharma Aktiengesellschaft
    06/04/19
  885. 308
    Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
    Amgen Inc
    06/04/19
  886. 33
    Compounds useful as inhibitors of ATR kinase
    Vertex Pharmaceuticals Incorporated
    06/04/19
  887. 16
    Dihydropyrrolopyridine inhibitors of ROR-gamma
    Vitae Pharmaceuticals Inc
    06/04/19
  888. 4
    Factor XIa inhibitors
    Merck Sharp & Dohme Corp
    06/04/19
  889. 17
    Glycine transporter-1 inhibitors
    Amgen Inc
    06/04/19
  890. 9
    Inhibitors of bruton's tyrosine kinase
    Hoffmann-La Roche Inc
    06/04/19
  891. 33
    Phosphonate compounds for treatment of complement mediated disorders
    Achillion Pharmaceuticals Inc
    06/04/19
  892. 119
    Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
    Millennium Pharmaceuticals Inc
    06/04/19
  893. 224
    Pyrimidine PDE10 inhibitors
    Merck Sharp & Dohme Corp
    06/04/19
  894. 292
    Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
    Merck Sharp & Dohme Corp
    06/04/19
  895. 21
    Sphingosine 1-phosphate receptor antagonists
    Arroyo BioSciences, LLC
    06/04/19
  896. 22
    Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections
    Gilead Sciences Inc
    06/04/19
  897. 28
    Substituted triazolopyridines and their use as TTK inhibitors
    Bayer Pharma Aktiengesellschaft
    06/04/19
  898. 96
    Tricyclic pyrido-carboxamide derivatives as rock inhibitors
    Bristol-Myers Squibb Company
    06/04/19
  899. 21
    3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose
    Sanwa Kagaku Kenkyusho Co., Ltd
    06/03/19
  900. 26
    Acetylcholinesterase inhibitors and promnesiant serotonin 5-HT4 receptor agonists, their methods of preparation and the pharmaceutical compositions containing the same
    UNIVERSITE DE CAEN
    06/03/19
  901. 240
    Aminopyrimidine derivatives for use as modulators of kinase activity
    Merck Patent GmbH
    06/03/19
  902. 295
    Benzodioxane inhibitors of leukotriene production for combination therapy
    Boehringer Ingelheim International GmbH
    06/03/19
  903. 66
    Cyclopropanecarboxylic acid derivative
    Daiichi Sankyo Company, Limited
    06/03/19
  904. 393
    Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer
    Agios Pharmaceuticals Inc
    06/03/19
  905. 307
    RORγ modulators
    Bristol-Myers Squibb Company
    06/03/19
  906. 209
    Sulfur derivatives as chemokine receptor modulators
    Allergan Inc
    06/03/19
  907. 207
    4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
    Array BioPharma Inc
    05/29/19
  908. 55
    Aminoester derivatives
    Chiesi Farmaceutici S.p.A.
    05/29/19
  909. 10
    Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors
    Leo Pharma A/S
    05/29/19
  910. 28
    Btk inhibitors
    Merck Sharp & Dohme Corp
    05/29/19
  911. 20
    Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
    Shanghai Hengrui Pharmaceutical Co., Ltd
    05/29/19
  912. 43
    Heteroaryl compounds as 5-HT4 receptor ligands
    Suven Life Sciences Limited
    05/29/19
  913. 33
    Heterocyclic compounds as inhibitors of class I PI3KS
    TBA
    05/29/19
  914. 21
    Heterocyclic sulfone RORγ modulators
    Bristol-Myers Squibb Company
    05/29/19
  915. 32
    Phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors
    Hoffman-La Roche Inc
    05/29/19
  916. 23
    Phenyl-dihydropyridine derivatives as inhibitors of aldosterone synthase
    Hoffmann-La Roche Inc
    05/29/19
  917. 34
    Purinone compounds as kinase inhibitors
    Pharmacyclics LLC
    05/29/19
  918. 538
    Purinones as ubiquitin-specific protease 1 inhibitors
    Forma Therapeutics Inc
    05/29/19
  919. 292
    Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
    Merck Sharp & Dohme Corp
    05/29/19
  920. 389
    Substituted 6,5-fused bicyclic heteroaryl compounds
    Epizyme Inc
    05/29/19
  921. 378
    Substituted 7-azabicycles and their use as orexin receptor modulators
    Janssen Pharmaceutica NV
    05/29/19
  922. 45
    Substituted pyrrolopyrimidines as HDM2 inhibitors
    Merck Sharp & Dohme Corp
    05/29/19
  923. 40
    Substituted tricyclic heterocyclic compounds
    Bristol-Myers Squibb Company
    05/29/19
  924. 15
    Tetrahydrocarboline derivative
    Ono Pharmaceutical Co., Ltd
    05/29/19
  925. 114
    Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
    Hoffman-La Roche Inc
    05/26/19
  926. 21
    Derivatives and methods of treating hepatitis B infections
    NOVIRA THERAPEUTICS, INC.
    05/26/19
  927. 181
    Non-nucleoside reverse transcriptase inhibitors
    Merck Sharp & Dohme Corp
    05/26/19
  928. 189
    Therapeutic compounds, compositions and methods of use thereof
    Genentech Inc
    05/26/19
  929. 171
    Alkoxy compounds for disease treatment
    ACUCELA INC.
    05/25/19
  930. 55
    Diacylglycerol acyltransferase 2 inhibitors
    Pfizer Inc
    05/25/19
  931. 86
    Factor IXa inhibitors
    Merck Sharp & Dohme Corp
    05/25/19
  932. 192
    Heteroaryl compounds and uses thereof
    Celgene CAR LLC
    05/25/19
  933. 27
    Imaging histone deacetylases with a radiotracer using positron emission tomography
    The General Hospital Corporation
    05/25/19
  934. 139
    Inhibiting agents for Bruton's tyrosine kinase
    BIOGEN MA INC.
    05/25/19
  935. 8
    Metabolism probes for therapy and diagnosis
    Vanderbilt University
    05/25/19
  936. 5
    Organic compounds
    Intra-Cellular Therapies Inc
    05/25/19
  937. 32
    PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
    Mitobridge, Inc.
    05/25/19
  938. 11
    Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives
    Allergan Inc
    05/25/19
  939. 103
    Pharmacologically active compounds
    Cancer Research Technology Limited
    05/25/19
  940. 191
    SGC stimulators
    Ironwood Pharmaceuticals, Inc.
    05/25/19
  941. 73
    Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
    Bayer Pharma Aktiengesellschaft
    05/25/19
  942. 162
    Substituted pyridines as inhibitors of human immunodeficiency virus replication
    ViiV HEALTHCARE UK (NO. 5) LIMITED
    05/25/19
  943. 7
    Tetrahydrothiophene-based GABA aminotransferase inactivators
    Northwestern University
    05/25/19
  944. 80
    Autotaxin inhibitors
    Novartis AG
    05/20/19
  945. 57
    Benzenesulfonamide compounds and their use as therapeutic agents
    Xenon Pharmaceuticals Inc
    05/20/19
  946. 100
    Compounds and compositions as inhibitors of MEK
    Novartis AG
    05/20/19
  947. 149
    Compounds useful as inhibitors of ATR kinase
    Vertex Pharmaceuticals Incorporated
    05/20/19
  948. 63
    Fused amino pyridine as HSP90 inhibitors
    Curis Inc
    05/20/19
  949. 19
    Multitarget FAAH and COX inhibitors and therapeutical uses thereof
    Fondazione Istituto Italiano di Tecnologia
    05/20/19
  950. 77
    Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics
    Galderma Research & Development
    05/20/19
  951. 29
    Pharmaceutically active pyrazine derivatives
    Sentinel Oncology Limited
    05/20/19
  952. 407
    1,3-thiazol-2-yl substituted benzamides
    Bayer Aktiengesellschaft
    05/16/19
  953. 74
    2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors
    Bayer Pharma Aktiengesellschaft
    05/16/19
  954. 60
    5H-pyrido[3,2-B]indole compounds as anticancer agents
    Bristol-Myers Squibb Company
    05/16/19
  955. 135
    6-morpholinyl-2-pyrazolyl-9H-purine derivatives and their use as PI3K inhibitors
    Daiichi Sankyo Company, Limited
    05/16/19
  956. 78
    Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists
    Boehringer Ingelheim International GmbH
    05/16/19
  957. 200
    Autotaxin inhibitors
    Novartis AG
    05/16/19
  958. 36
    Compounds as diacylglycerol acyltransferase inhibitors
    GlaxoSmithKline LLC
    05/16/19
  959. 28
    Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
    UNIVERSITE DE LILLE 2 DROIT ET SANTE
    05/16/19
  960. 116
    Cyclopropylamines as LSD1 inhibitors
    Incyte Corporation
    05/16/19
  961. 205
    Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors
    Merck Sharp & Dohme Corp
    05/16/19
  962. 21
    Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
    Redx Pharma PLC
    05/16/19
  963. 62
    Fused pyridines as kinase inhibitors
    Bristol-Myers Squibb Company
    05/16/19
  964. 300
    Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors
    Axovant Sciences GmbH
    05/16/19
  965. 22
    Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof
    SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD
    05/16/19
  966. 93
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    05/16/19
  967. 103
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    05/16/19
  968. 4
    Inhibitors of RET
    BLUEPRINT MEDICINES CORPORATION
    05/16/19
  969. 10
    Isoxazole carboxamides as irreversible SMYD inhibitors
    Epizyme Inc
    05/16/19
  970. 16
    JAK kinase inhibitor compounds for treatment of respiratory disease
    THERAVANCE BIOPHARMA R&D IP, LLC
    05/16/19
  971. 132
    Melanocortin receptor-specific peptides
    Palatin Technologies Inc
    05/16/19
  972. 14
    Oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection
    Hoffmann-La Roche Inc
    05/16/19
  973. 64
    Pyrazole compound
    Sumitomo Dainippon Pharma Co., Ltd
    05/16/19
  974. 49
    Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors
    AstraZeneca AB
    05/16/19
  975. 10
    Pyridone or pyrimidone derivative, preparation method therefor and application thereof
    SICHUAN HAISCO PHARMACEUTICAL CO., LTD.
    05/16/19
  976. 335
    Pyrimido-pyridazinone compounds and methods of use thereof
    Asana BioSciences, LLC
    05/16/19
  977. 110
    Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof
    Taiho Pharmaceutical Co., Ltd
    05/16/19
  978. 36
    Rho kinase inhibitors
    Kadmon Corporation LLC
    05/16/19
  979. 42
    Spiro-cyclic amine derivatives as S1P modulators
    AbbVie B.V.
    05/16/19
  980. 258
    Substituted 2-azabicycles and their use as orexin receptor modulators
    Janssen Pharmaceutica NV
    05/16/19
  981. 143
    Substituted oxopyridine derivatives and use thereof cardiovascular disorders
    Bayer Pharma Aktiengesellschaft
    05/16/19
  982. 716
    Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Array BioPharma Inc
    05/16/19
  983. 716
    Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
    Array BioPharma Inc
    05/16/19
  984. 121
    Therapeutic compounds and uses thereof
    Genentech Inc
    05/16/19
  985. 45
    Triazolo[4,5-D]pyrimidines
    Hoffmann-La Roche Inc
    05/16/19
  986. 17
    Tricyclic compounds and uses thereof in medicine
    Sunshine Lake Pharma Co., Ltd
    05/16/19
  987. 384
    sGC stimulators
    Ironwood Pharmaceuticals, Inc.
    05/16/19
  988. 411
    1,3-thiazol-2-yl substituted benzamides
    BEYER AKTIENGESELLSCHAFT
    05/15/19
  989. 15
    2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
    Merck Sharp & Dohme Corp
    05/15/19
  990. 3
    Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
    Merck Sharp & Dohme Corp
    05/15/19
  991. 18
    Aminoindazole derivatives as sodium channel inhibitors
    Almirall, S.A.
    05/15/19
  992. 8
    Aniline derivatives, their preparation and their therapeutic application
    Sanofi
    05/15/19
  993. 27
    Benzimidazole derivatives as kinase inhibitors
    Selvita S.A.
    05/15/19
  994. 32
    Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
    Pfizer Inc
    05/15/19
  995. 15
    Compounds and methods for inhibition of AP endonuclease-1/redox factor-1 (HAPE1) activity
    University of Pittsburgh
    05/15/19
  996. 207
    Compounds and methods for kinase modulation, and indications therefor
    Plexxikon Inc.
    05/15/19
  997. 156
    Dihydropyrrolopyridine inhibitors of ROR-gamma
    Vitae Pharmaceuticals Inc
    05/15/19
  998. 61
    Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
    Forma Therapeutics Inc
    05/15/19
  999. 22
    Heteroaryl compounds as sodium channel blockers
    Purdue Pharma LP
    05/15/19
  1000. 24
    Heterocyclic compounds and methods for their use
    Novartis AG
    05/15/19
  1001. 83
    Heterocyclic compounds and methods of their use
    Novartis AG
    05/15/19
  1002. 98
    Heterocyclic compounds, process for preparation of the same and use thereof
    Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    05/15/19
  1003. 154
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    05/15/19
  1004. 106
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    05/15/19
  1005. 12
    IDO inhibitors
    Bristol-Myers Squibb Company
    05/15/19
  1006. 370
    Inhibitors of ERK and methods of use
    Kura Oncology Inc
    05/15/19
  1007. 20
    Inhibitors of bruton's tyrosine kinase
    F. Hoffmann-La Roche Inc
    05/15/19
  1008. 28
    Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
    Signal Pharmaceuticals, LLC
    05/15/19
  1009. 5
    N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine
    GLUCOX BIOTECH AB
    05/15/19
  1010. 12
    Nuclear receptor binding agents
    GTX Inc
    05/15/19
  1011. 27
    Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
    Novartis AG
    05/15/19
  1012. 15
    Pyridazinone macrocycles as IRAK inhibitors and uses thereof
    Merck Patent GmbH
    05/15/19
  1013. 6
    Pyridine compounds used as PI3 kinase inhibitors
    Teligene Ltd
    05/15/19
  1014. 32
    Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors
    Eli Lilly and Company
    05/15/19
  1015. 18
    Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
    Pfizer Inc
    05/15/19
  1016. 6
    Substituted 6,5-fused bicyclic heteroaryl compounds
    Epizyme Inc
    05/15/19
  1017. 21
    Substituted bipiperidinyl derivatives
    Bayer Pharma Aktiengesellschaft
    05/15/19
  1018. 46
    Substituted heterocyclic derivative, preparation method and use thereof
    Xiamen University
    05/15/19
  1019. 14
    Substituted piperidinyltetrahydroquinolines
    Bayer Pharma Aktiengesellschaft
    05/15/19
  1020. 52
    Substituted quinazolines for inhibiting kinase activity
    NEUPHARMA, INC.
    05/15/19
  1021. 589
    Sulfone amide linked benzothiazole inhibitors of endothelial lipase
    Bristol-Myers Squibb Company
    05/15/19
  1022. 277
    Tricyclic heterocycles as BET protein inhibitors
    Incyte Corporation
    05/15/19
  1023. 17
    URAT1 inhibitor
    Nippon Chemiphar Co., Ltd
    05/15/19
  1024. 36
    Thioether-piperidinyl orexin receptor antagonists
    Merck Sharp & Dohme Corp
    05/10/19
  1025. 150
    4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity
    VIROSTATICS SRL
    05/08/19
  1026. 62
    Antibacterial cyclopental[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
    Janssen Sciences Ireland UC
    05/08/19
  1027. 86
    Compounds and methods for kinase modulation, and indications therefor
    Plexxikon Inc.
    05/08/19
  1028. 44
    Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
    AbbVie Deutschland GmbH & Co. KG
    05/08/19
  1029. 68
    Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors
    BeiGene, Ltd
    05/08/19
  1030. 45
    Histone deacetylase inhibitors and compositions and methods of use thereof
    CHDI Foundation Inc
    05/08/19
  1031. 77
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    05/08/19
  1032. 8
    Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments
    LABORATORIES DEL DR. ESTEVE S.A.
    05/08/19
  1033. 34
    Inhibitors of bruton's tyrosine kinase
    Hoffmann-La Roche Inc
    05/08/19
  1034. 216
    Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases
    BIOGEN MA INC.
    05/08/19
  1035. 96
    N-substituted pyrazolo [3,4-D] pyrimidine ketone compound, and preparation process and use thereof
    Sun Yat-sen University
    05/08/19
  1036. 88
    Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
    North Carolina Central University
    05/08/19
  1037. 13
    Pyridin-4-yl derivatives
    Actelion Pharmaceuticals Ltd
    05/08/19
  1038. 315
    Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
    Pfizer Inc
    05/08/19
  1039. 11
    Substituted pyridinone compounds as MEK inhibitors
    CMG PHARMACEUTICAL CO., LTD.
    05/08/19
  1040. 72
    Triazolo compounds
    Hoffmann-La Roche Inc
    05/08/19
  1041. 10
    Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
    NewLink Genetics Corporation
    05/08/19
  1042. 15
    1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
    AstraZeneca AB
    05/07/19
  1043. 48
    Alkynyl indazole derivative and use thereof
    Senju Pharmaceutical Co., Ltd
    05/07/19
  1044. 77
    Rho kinase inhibitors and methods of use
    H. Lee Moffitt Cancer Center and Research Institute Inc
    05/07/19
  1045. 4
    Substituted indazole derivatives active as kinase inhibitors
    Nerviano Medical Sciences srl
    05/07/19
  1046. 122
    2,4-diaminopyrimidine derivatives as histamine H4 modulators
    Janssen Pharmaceutica NV
    04/30/19
  1047. 330
    Arylquinazolines
    Merck Patent GmbH
    04/30/19
  1048. 42
    Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
    Incyte Corporation
    04/30/19
  1049. 95
    Combination pharmaceutical compositions and uses thereof
    Intellikine LLC
    04/30/19
  1050. 14
    Inhibitors of CYP17A1
    University of Kansas
    04/30/19
  1051. 11
    Insulin sensitisers and methods of treatment
    Naia Metabolic, Inc.
    04/30/19
  1052. 59
    Permeable glycosidase inhibitors and uses thereof
    Alectos Therapeutics Inc
    04/30/19
  1053. 79
    Piperidine derivatives
    Hoffmann-La Roche Inc
    04/30/19
  1054. 259
    Substituted 2-azabicycles and their use as orexin receptor modulators
    Janssen Pharmaceutica NV
    04/30/19
  1055. 814
    Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Array BioPharma Inc
    04/30/19
  1056. 556
    Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Array BioPharma Inc
    04/30/19
  1057. 157
    Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
    Bayer Pharma Aktiengesellschaft
    04/30/19
  1058. 389
    Therapeutically active compounds and their methods of use
    Agios Pharmaceuticals Inc
    04/30/19
  1059. 39
    1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders
    LABORATORIOS DEL DR. ESTEVE S.A.
    04/29/19
  1060. 34
    1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
    AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.
    04/29/19
  1061. 177
    Antiproliferative benzo [B] azepin-2-ones
    Hoffmann-La Roche Inc
    04/29/19
  1062. 15
    Compounds for the treatment and prevention of retroviral infections
    KFLP BIOTECH, LLC
    04/29/19
  1063. 12
    Compounds for the treatment of addiction
    Gilead Sciences Inc
    04/29/19
  1064. 93
    Histone demethylase inhibitors
    Celgene Quanticel Research Inc
    04/29/19
  1065. 10
    Macrocyclic insulin-degrading enzyme (IDE) inhibitors and uses thereof
    President and Fellows of Harvard College
    04/29/19
  1066. 8
    Oxazolidinone and imidazolidinone compounds
    Hoffmann-La Roche Inc
    04/29/19
  1067. 397
    Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
    Amgen Inc
    04/29/19
  1068. 151
    Pyridine compounds and the uses thereof
    Purdue Pharma LP
    04/29/19
  1069. 129
    Substituted 2-azabicycles and their use as orexin receptor modulators
    Janssen Pharmaceutica NV
    04/29/19
  1070. 192
    Substituted piperidine compounds and their use as orexin receptor modulators
    Janssen Pharmaceutica NV
    04/29/19
  1071. 3
    Substituted pyridine derivatives useful as C-FMS kinase inhibitors
    Janssen Pharmaceutica NV
    04/29/19
  1072. 232
    Substituted tricyclic compounds as FGFR inhibitors
    Incyte Holdings Corporation
    04/29/19
  1073. 145
    Therapeutic inhibitory compounds
    LIFESCI PHARMACEUTICALS, INC.
    04/29/19
  1074. 79
    Tropomyosin-related kinase (TRK) inhibitors
    Genzyme Corporation
    04/29/19
  1075. 111
    1-(3-aminopropyl) substituted cyclic amine compounds, preparation method therefor, and pharmaceutical compositions and uses thereof
    Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    04/24/19
  1076. 5
    1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer
    Cancer Research Technology Limited
    04/24/19
  1077. 118
    2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
    Pfizer Inc
    04/24/19
  1078. 9
    2-oxo-3,4-dihydroquinolin-6-yl sulphonamide CPDS and their use as plant growth regulators
    University of California
    04/24/19
  1079. 15
    5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines
    Hoffmann-La Roche Inc
    04/24/19
  1080. 198
    Alkynyl alcohols and methods of use
    Genentech Inc
    04/24/19
  1081. 37
    Benzodiazepines as bromodomain inhibitors
    Catalyst Therapeutics Pty Ltd.
    04/24/19
  1082. 21
    Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof
    Bayer Pharma Aktiengesellschaft
    04/24/19
  1083. 305
    Compounds and compositions as RAF kinase inhibitors
    Novartis AG
    04/24/19
  1084. 69
    Compounds and methods for inhibiting JAK
    Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    04/24/19
  1085. 95
    Inhibitors of the renal outer medullary potassium channel